documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report part item business general bristolmyers squibb company may referred bristolmyers squibb bms company us incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis last years executed strategy transform next generation biopharmaceutical company transformation encompassed areas business operations part strategy divested nonpharmaceutical businesses implemented acquisition licensing strategy known stringofpearls executed productivity transformation initiative pti divestitures included medical imaging january convatec august mead johnson december acquisition licensing transactions included kosan biosciences inc june medarex inc medarex september zymogenetics inc zymogenetics october amira pharmaceuticals inc amira september inhibitex inc inhibitex february well several license arrangements continue review cost structure intent maintain modernized efficient robust balance building competitive advantages securing innovative products planning future report financial operating information one segmentbiopharmaceuticals additional information business segments see item financial statementsnote business segment information compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products united states us puerto rico foreign countries us net sales accounted total net sales total net sales net sales europe accounted total net sales net sales japan accounted total net sales net sales canada accounted total net sales products pharmaceutical products include chemicallysynthesized drugs small molecules increasing portion products produced biological processes typically involving recombinant dna technology called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections infusion revenues come products following therapeutic classes cardiovascular virology including human immunodeficiency virus hiv infection oncology neuroscience immunoscience metabolics pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity business focused innovative biopharmaceutical products rely patent rights forms regulatory protection maintain market exclusivity products us european union eu countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion patent rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition business see generic competition following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan canada also sell pharmaceutical products countries however data provided countrybycountry basis individual country sales significant outside us eu japan canada many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products casebycase basis purposes business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate following schedule presents net sales key products estimated basic exclusivity loss us eu japanese canadian markets net sales products past currently estimated year basic exclusivity loss dollars millions us eu japan canada key products plavix b avaproavalide eliquis na na abilify c e reyataz f sustiva franchise g h baraclude erbitux j j sprycel k yervoy na na j j orencia j j l nulojix na na onglyzakombiglyze note currently estimated earliest year basic exclusivity loss includes statutory extensions exclusivity earned yet granted instances may able obtain additional six months exclusivity product based pediatric extension example certain instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position products product exclusivity predicted assured us healthcare law enacted qualifying biologic products receive years data exclusivity biosimilar enter market described detail intellectual property product exclusivity indicates brand names products trademarks owned bristolmyers squibb subsidiaries specific trademark ownership information found currently market product country region indicated references eu throughout include member states members european union year ended december basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states eu countries basic patent obtained may data protection available b data exclusivity eu expired july major markets within europe product national patents expiring specifically claim bisulfate form clopidogrel however generic alternate salt forms clopidogrel bisulfate marketed compete plavix throughout eu c rights commercialize abilify aripiprazole us terminate rights commercialize abilify eu terminate e exclusivity period based regulatory data protection f data exclusivity eu expires g exclusivity period relates sustiva brand include exclusivity related combination therapy composition matter patent efavirenz us expires method use patent treatment hiv infection expires h exclusivity period relates sustiva brand include exclusivity related combination therapy market exclusivity sustiva expected expire countries eu data exclusivity sustiva expired eu biologic product approved biologics license application bla data exclusivity us expires patent specifically claims composition matter cetuximab active ingredient erbitux rights commercialize cetuximab terminate j exclusivity period based regulatory data protection k pending patent application eu member states l data exclusivity canada expires summary indication intellectual property position product partner thirdparty manufacturing arrangements products us applicable eu japan canada plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codeveloped jointly marketed sanofi information alliance sanofi see strategic alliances collaborations item financial statementsnote alliances collaborations composition matter patent us expires may including pediatric extension eu regulatory data exclusivity protection expired july major markets within europe plavix benefits national patents expiring specifically claim bisulfate form clopidogrel however generic alternative salt forms clopidogrel bisulfate marketed compete throughout eu obtain bulk requirements clopidogrel bisulfate sanofi thirdparty company sanofi finish product respective facilities avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi information alliance sanofi see strategic alliances collaborations item financial statementsnote alliances collaborations composition matter patent us expires march including pediatric extension countries eu data exclusivity eu expired august avapro october avalide composition matter patent expired canada march irbesartan manufactured company sanofi manufacture bulk requirements irbesartan finish avaproavalide facilities avalide purchase bulk requirements hydrochlorothiazide thirdparty eliquis eliquis apixaban oral factor xa inhibitor targeted prevention treatment venous thromboembolic vte disorders stroke prevention atrial fibrillation currently approved eu use vte prevention adult patients undergone elective hip knee replacement surgery currently registrational process us eu prevention stroke systemic embolism patients atrial fibrillation apixaban discovered internally part alliance pfizer inc pfizer information alliance pfizer see item financial statementsnote alliances collaborations composition matter patent covering apixaban us expires eu expires data exclusivity eu expires manufacture bulk requirements apixaban finish product facilities abilify abilify aripiprazole atypical antipsychotic agent adult patients schizophrenia bipolar mania disorder major depressive disorder abilify also pediatric uses schizophrenia bipolar disorder among others global commercialization agreement otsuka pharmaceutical co ltd otsuka except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt information arrangement otsuka see strategic alliances collaborations item financial statementsnote alliances collaborations basic us composition matter patent abilify term current abilify agreement expire april including granted patent term extension six month pediatric extension basic composition matter patent protecting aripiprazole subject patent litigation us otsuka sole rights enforce patent information litigation matter see item financial statements legal proceedings contingencies composition matter patent force germany united kingdom uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplementary protection certificate countries except romania denmark data exclusivity rights commercialize eu expire data exclusivity canada expires obtain bulk requirements aripiprazole otsuka company otsuka finish product respective facilities reyataz reyataz atazanavir sulfate protease inhibitor treatment hiv developed atazanavir worldwide license novartis pharmaceutical corporation novartis royalty paid based percentage net sales entitled promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories abbott amended royalty paid based percentage net sales recently entered licensing agreement gilead sciences inc develop commercialize fixeddose combination containing reyataz one gileads compounds development market exclusivity reyataz expected expire us canada major eu member countries japan data exclusivity eu expires manufacture bulk requirements atazanavir finish product facilities sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet three drug regimen combining sustiva gilead sciences incs gilead truvada emtricitabine tenofovir disoproxil fumarate atripla first complete highly active antiretroviral therapy treatment product hiv available us fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together help simplify hiv therapy patients providers information arrangement gilead see strategic alliances collaborations item financial statementsnote alliances collaborations rights market efavirenz us canada united kingdom uk france germany ireland italy spain licensed merck co inc royalty based percentage net sales composition matter patent efavirenz us expires method use patent treatment hiv infection expires possible additional six month pediatric extension market exclusivity sustiva expected expire countries eu data exclusivity sustiva expired eu another company market efavirenz japan certain atripla patents subject patent litigation us time us patents covering efavirenz composition matter method use challenged eu patent efavirenz subject litigation netherlands germany uk information litigation matters see item financial statementsnote legal proceedings contingencies obtain bulk requirements efavirenz third parties produce finished goods facilities provide bulk efavirenz gilead responsible producing finished atripla product baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approved fda treatment chronic hepatitis b infection baraclude discovered developed internally also approved marketed countries outside us including china japan eu composition matter patent expires us patent subject patent litigation us information litigation matter see item financial statementsnote legal proceedings contingencies composition matter patent expires eu japan composition matter patent expired canada uncertainty chinas exclusivity laws resulted generic competition china market manufacture bulk requirements entecavir finish product facilities erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved treatment combination irinotecan treatment patients egfrexpressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan fda also approved erbitux use treatment squamous cell carcinoma head neck specifically erbitux approved use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed fda also approved erbitux firstline recurrent locoregional metastatic head neck cancer combination platinum based chemotherapy fluorouracil erbitux marketed north america us agreement imclone systems incorporated imclone predecessor company imclone llc whollyowned subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october imclone merck kgaa merck japan erbitux received marketing approval japan july use treating patients advanced recurrent colorectal cancer description alliance imclone see strategic alliances collaborations item financial statementsnote alliances collaborations data exclusivity us expires patent specifically claims composition matter cetuximab active molecule erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination antineoplastic agent approved fda combination use claimed granted us patent expires including granted patent term extension inventorship use patent challenged three researchers yeda research development company ltd yeda pursuant settlement agreement executed announced december imclone sanofi yeda end worldwide litigation related use patent sanofi yeda granted imclone worldwide license use patent data exclusivity japan canada expire yeda right license use patent others yedas license patent third parties could result product competition erbitux might otherwise occur unable assess whether extent competitive impact occur quantify impact however yeda granted amgen inc amgen license use patent amgen received fda approval market egfrproduct competes erbitux obtain finished goods requirements cetuximab use north america lilly lilly manufactures bulk requirements cetuximab facilities finishing performed thirdparty lilly description supply agreement lilly see manufacturing quality assurance sprycel sprycel dasatinib multitargeted tyrosine kinase inhibitor approved treatment adults phases chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib mesylate treatment adults philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy fda approved sprycel treatment adult patients newly diagnosed philadelphia chromosomepositive ph chronic myeloid leukemia cml chronic phase sprycel internally discovered part strategic alliance otsuka information alliance otsuka see strategic alliances collaborations item financial statementsnote alliances collaborations patent term extension granted us extending term basic composition matter patent covering dasatinib june dasatinib subject patent litigation us information litigation matter see item financial statementsnote legal proceedings contingencies us orphan drug exclusivity expires protects product generic applications currently approved orphan indications several eu countries patent pending upon grant would expire april excluding term extensions manufacture bulk requirements dasatinib finish product facilities yervoy yervoy ipilimumab biological product monoclonal antibody treatment patients unresectable inoperable metastatic melanoma ipilimumab approved fda march ema july currently also studied indications including lung cancer well adjuvant melanoma hormonerefractory prostate cancer information research development yervoy see research development yervoy discovered medarex codeveloped company medarex subsidiary patent covering ipilimumab composition matter currently expires us eu data exclusivity expires us eu obtain bulk ipilimumab thirdparty manufacturer finish product third party facility orencia orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderate severe rheumatoid arthritis inadequate response certain currently available treatments abatacept available intravenous formulation beginning subcutaneous formulation us orencia discovered developed internally series patents covering abatacept method use us patent term extension granted one composition matter patents extending term us patent majority eu countries patent covering abatacept expires applied supplementary protection certificates also pediatric extension supplementary protection certificates protection protection certificates granted data exclusivity us eu expires obtain bulk abatacept thirdparty manufacturer finish product facilities formulations nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity prevention kidney transplant rejection approved launched us june approved eu june launched july belatacept internally discovered developed patent covering belatacept composition matter expires april us may eu data exclusivity expires us june eu june manufacture bulk requirements belatacept finish products facilities onglyza kombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicated treatment type diabetes adjunct diet exercise kombiglyze saxagliptin metformin hydrochloride extendedrelease approved us combination product indicated adjunct diet exercise improve glycemic control adults type diabetes mellitus treatment saxagliptin metformin appropriate komboglyze saxagliptin metformin immediaterelease approved eu combination product indicated adjunct diet exercise improve glycemic control adults type diabetes mellitus inadequately controlled maximally tolerated dose metformin alone already treated combination saxagliptin metformin separate tablets document unless specifically noted refer kombiglyze komboglyze kombiglyze onglyza internally discovered company kombiglyze codeveloped company astrazeneca plc astrazeneca worldwide except japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement astrazeneca otsuka japan see strategic alliances collaborations item financial statementsnote alliances collaborations patent covering saxagliptin composition matter expires march us eu manufacture bulk requirements saxagliptin facilities obtain bulk metformin kombiglyze third party company astrazeneca finish onglyza facilities company finishes kombiglyze facility emerging markets compete emerging markets encompassed various regional organizations emerging markets regional organization comprised brazil russia india china turkey identified countries significant opportunities growth emerging markets characterized strong economic development rising gross domestic product growing middle class increasing wealth amongst middle class well demand quality healthcare emerging markets may provide growth opportunity pharmaceuticals industry middle next decade strategy capitalize growth opportunity innovationfocused approach approach plan develop commercialize select innovative products key high growth markets tailoring approach market individually emerging public health interests countries best align strategy well current portfolio pipeline countries also identified improving intellectual property protection order capitalize growth opportunities emerging markets must balance related risks well develop innovative pricing access strategies make products accessible patients provide reasonable return investment risks markets include intellectual property protection governmentmandated authorized generics currency volatility reimbursement issues government stability scale issues monitor mitigate risks extent possible research development invest heavily research development rd believe critical longterm competitiveness major rd facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development also carried various facilities throughout world including belgium uk india sites us supplement internal drug discovery development programs alliances collaborative agreements agreements bring new products pipeline help us remain cutting edge technology search novel medicines drug development engage services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products management continues emphasize leadership innovation productivity quality strategies success research development activities concentrate biopharmaceutical research development efforts following disease areas significant unmet medical need affective psychiatric disorders pain alzheimersdementia cardiovascular diabetes hepatitis hivaids oncology immunologic disorders solid organ transplant fibrotic disease also continue analyze may selectively pursue promising leads areas addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug includes phase phase ii phase iii clinical trials designed specifically support new drug application particular indication assuming trials successful phase clinical trials involve small number healthy patients patients suffering indicated disease test safety proper dosing phase ii clinical trials involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical trials conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate rd process typically takes thirteen years longer three years often spent phase iii latestage development consider rd programs phase iii latestage development significant rd programs programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations drug development time consuming expensive risky average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately compounds enter phase development fail achieve regulatory approval failure rate compounds enter phase ii development approximately compounds enter phase iii development approximately total research development expenses include costs discovery research preclinical development early lateclinical development drug formulation well clinical trials medical support marketed products proportionate allocations enterprisewide costs appropriate costs spent billion billion research development activities research development spending includes payments third party collaborations contracts end employed approximately people rd activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years listed several latestage investigational compounds phase iii clinical trials least one potential indication whether investigational compounds ultimately becomes one marketed products depends results clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance seek regulatory approval compounds approval sought obtained also assurance compound approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted includes patent term extensions granted brivanib brivanib oral small molecule dual kinase inhibitor blocks vegf receptor fgf receptor currently phase iii trials anticancer treatment potential use hepatocellular carcinoma colorectal cancer patent covering brivanib composition matter expires us dapagliflozin dapagliflozin oral sglt inhibitor potential treatment diabetes currently registrational process eu us discovered internally part alliance astrazeneca patent covering dapagliflozin composition matter expires october us january received complete response letter regarding nda dapagliflozin discussion see item managements discussion analysis financial condition results operationsproduct pipeline developments necitumumab imcf necitumumab fully human monoclonal antibody investigated anticancer treatment discovered imclone part alliance company lilly phase iii trials non small cell lung cancer lilly owns patent covering necitumumab composition matter expires us elotuzumab elotuzumab humanized monoclonal antibody investigated anticancer treatment discovered pdl biopharma became part facet biotech corporation facet spinoff facet subsequently acquired abbott part alliance abbott phase iii trials multiple myeloma abbott owns patent covering elotuzumab composition matter expires us daclatasvir daclatasvir oral small molecule nsa replication complex inhibitor phase iii development treatment hepatitis c virus patent covering daclatasvir composition matter expires us following table lists potential additional indications key marketed products phase iii development currently regulatory review eliquis potential indications stroke prevention atrial fibrillation vte treatment orencia potential additional indication lupus nephritis sprycel potential additional indication prostate cancer yervoy potential additional indications adjuvant melanoma prostate cancer nonsmall cell lung cancer small cell lung cancer potential additional indication firstline metastatic melanoma eu erbitux potential additional indications firstline colorectal cancer firstline secondline nonsmall cell lung cancer gastric cancer onglyza potential additional use cardiovascular risk reduction pediatric extension sustiva potential pediatric extension baraclude potential pediatric extension following key developments currently expected occur respect significant pipeline programs outcome timing expected developments dependent upon number factors including among things availability data outcome certain clinical trials acceptance presentations certain medical meetings andor actions health authorities undertake obligation publicly update information whether result new information future events otherwise eliquis potential us eu approval stroke prevention atrial fibrillation dapagliflozin potential eu approval treatment type diabetes data available phase iii studies patients cardiovascular disease data available phase iii study addon sitagliptin onglyza data available phase iii study addon metformin sulfonylurea nulojix fouryear data available phase iii studies subpopulation analyses orencia data available headtohead study versus humira potential eu approval subcutaneous formulation phase iii start lupus nephritis phase iii start psoriatic arthritis yervoy submission dtic combination data us eu ipilimumab plus vemurafenib safetyfeasibility data available brivanib data available phase iii study advanced hepatocellular cancer erbitux potential approval firstline colorectal cancer sprycel threeyear data first line cml daclatasvir data available phase ii hepatitis c combination studies strategic alliances collaborations enter strategic alliances collaborations third parties give us rights develop manufacture market andor sell pharmaceutical products owned third parties give third parties rights develop manufacture market andor sell pharmaceutical products owned us alliances collaborations take many forms including licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances arrangements reduce risk incurring research development expenses compounds lead revenuegenerating products however profitability alliance products generally lower sometimes substantially profitability products partnered profits alliance products shared alliance partners assurance new alliances formed actively pursue arrangements view alliances important complement discovery development activities strategic alliances arrangements third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured number alliance agreements also permit collaborator us terminate without cause typically exercisable substantial advance written notice often exercisable specified period time elapsed collaboration agreement signed strategic alliances arrangements typically otherwise contain provisions provide party right terminate alliance short notice general retain rights product brought alliance another party partys intellectual property alliance terminates loss rights one products marketed sold us pursuant strategic alliance arrangement could material results operations cash flows case plavix abilify could material financial condition liquidity customary pharmaceutical industry terms strategic alliances arrangements generally coextensive exclusivity period may vary countrybycountry basis significant current alliances arrangements currently marketed products investigational compounds described current marketed productsinlicensed sanofi agreements sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromoted certain countries outside us tradename aprovelcoaprovel comarketed certain countries outside us us tradename karveakarvezide plavix copromoted certain countries outside us tradename plavix comarketed certain countries outside us us tradename iscover worldwide alliance operates framework two geographic territories one covering certain european asian countries referred territory one covering us puerto rico canada australia certain latin american countries referred territory b territory b managed two separate sets agreements one plavix us puerto rico products australia mexico brazil colombia argentina separate set agreements avaproavalide us puerto rico within territory territory partnership exists supply finished product country within territory manage contract certain central expenses marketing research development royalties countries within territories b structured local affiliate sanofis local affiliate either comarket separate brands ie affiliate operates independently competes selling product different trademarks copromote single brand ie product trademark within territory comarketing countries include germany spain italy irbesartan greece china clopidogrel bisulfate sell iscover karveakarvezide sanofi sells plavix aprovelcoaprovel countries except china retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden taiwan south korea hong kong aprovelcoaprovel certain french export countries prior company sanofi also copromoted plavix singapore sanofi acts operating partner territory owns financial controlling interest territory ownership interest territory account investment partnership entities territory equity method recognize share results equity net income affiliates share net income partnership entities taxes million million million within territory b company sanofi copromote plavix avaproavalide us canada puerto rico territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing countries act operating partner territory b majority controlling interest territory consolidate partnership results territory b recognize sanofis share results net earnings attributable noncontrolling interest net taxes million million million recognized net sales territory b territory comarketing countries billion billion billion territory partnerships governed series committees enumerated functions powers responsibilities territory two senior committees final decisionmaking authority respect territory enumerated functions powers responsibilities within jurisdictions agreements sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights relating products applicable territory alliance arrangements may terminated sanofi us either whole affected country territory depending circumstances event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continues days order decree approving continues unstayed effect days ii material breach obligation major alliance agreement remains uncured days following notice breach except commencement diligent prosecution cure occurred within days notice iii deadlocks one senior committees render continued commercialization product impossible given country territory iv increase combined cost goods royalty exceeds specified percentage net selling price product v good faith determination terminating party commercialization product terminated reasons patient safety case termination rights agreements include provisions termination relevant alliance respect applicable product applicable country territory case termination due bankruptcy insolvency material breach products applicable territory termination procedures slightly different however events could lose rights either products applicable relevant country territory even case bankruptcy insolvency material breach defaulting party discussion strategic alliance sanofi see item financial statementsnote alliances collaborations otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement excluding certain asia pacific countries april company otsuka agreed extend us portion commercialization manufacturing agreement expected loss product exclusivity april contractual share abilify net sales recognized company pursuant extension beginning january contractual share revenue recognized company reduced uk germany france spain company receives thirdparty net sales countries us thirdparty customers invoiced company behalf otsuka alliance revenue recognized abilify shipped risks rewards ownership transferred third party customers also exclusive right sell abilify countries europe americas number countries asia countries recognize net sales terms abilify agreement amended purchase product otsuka perform finish manufacturing sale us otsuka third party customers terms extension agreement paid otsuka million amortized reduction net sales extension period unamortized balance included assets otsuka receives royalty based total us net sales included cost products sold otsuka responsible us expenses related commercialization abilify reimbursements netted principally marketing selling administrative advertising product promotion expenses abilify agreement expires april us june eu countries country exclusive right sell abilify agreement expires later april loss exclusivity country beginning january expected loss us exclusivity april receive following percentages us annual net sales share us net sales billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible us expenses related commercialization abilify us us portion abilify agreement oncology agreement described include changeofcontrol provision acquired acquiring company competing product abilify new company assume abilify agreement amended oncology agreement currently exists acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights abilify agreement amended price according predetermined schedule agreements also provide event generic competitor abilify option terminating abilify april amendment agreement previously amended remaining force exercise option either would receive payment otsuka according predetermined schedule oncology agreement would terminate time ii oncology agreement would continue truncated period according predetermined schedule early termination abilify agreement immediate upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event challenge otsukas patent rights marketbymarket basis event market product direct competition abilify upon termination expiration abilify agreement retain rights abilify recognized net sales abilify billion billion addition million extension payment total upfront milestone licensing payments made otsuka abilify agreement million discussion oncology agreement otsuka see current marketed productsinternally discovered discussion strategic alliance otsuka see item financial statementsnote alliances collaborations lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux necitumumab imcf us canada japan information agreement respect necitumumab see investigational compounds developmentinlicensed egfr agreement respect erbitux sales north america lilly receives distribution fee based flat rate net sales north america plus reimbursement certain royalties paid lilly company lilly share one half profits losses evenly japan merck kgaa receiving half profits losses japan parties share royalties payable third parties pursuant formula set forth commercialization agreement purchase north american commercial requirements bulk erbitux lilly agreement expires erbitux north america september early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice us exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance retain rights erbitux share codevelopment copromotion rights erbitux merck kgaa japan agreement signed october expiring lilly merck kgaa merck japan lilly ability terminate agreement determines commercially unreasonable continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer recognized net sales erbitux million million million discussion strategic alliance lilly see item financial statementsnote alliances collaborations gilead joint venture gilead develop commercialize atripla us canada europe company gilead share responsibility commercializing atripla us canada throughout eu certain european countries provide funding fieldbased sales representatives support promotional efforts atripla gilead recognizes atripla revenues us canada countries europe revenue efavirenz component determined applying percentage atripla revenue approximate revenue sustiva brand recognized efavirenz revenues million million million related atripla net sales joint venture company gilead continue terminated mutual agreement parties otherwise described event material breach one party nonbreaching party may terminate joint venture parties agree desirable practicable withdraw combination product markets commercialized time one generic versions partys component products appear market us party right terminate joint venture thereby acquire rights combination product us canada however three years terminated party continue receive percentage net sales based contribution bulk components atripla otherwise retains rights products entered licensing agreement gilead develop commercialize fixeddose combination containing reyataz gileads cobicistat pharmacoenhancing boosting agent currently phase iii clinical trials increases blood levels certain hiv medicines potentially allow one pill daily dosing discussion strategic alliance gilead see item financial statementsnote alliances collaborations current marketed productsinternally discovered astrazeneca january entered worldwide except japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement kombiglyze codeveloped astrazeneca saxagliptin agreement exclusive rights develop sell onglyza japan licensed otsuka december described investigational compounds developmentinternally discovered company astrazeneca also parties worldwide codevelopment cocommercialization agreement dapagliflozin described investigational compounds developmentinternally discovered manufacture onglyza kombiglyze certain limited exceptions recognize net sales key markets received million upfront milestone licensing payments astrazeneca meeting certain development regulatory milestones onglyza kombiglyze including million received million received could receive additional million salesbased milestones met majority costs initial development plans paid astrazeneca additional development costs generally shared equally expense onglyza kombiglyze development costs net astrazenecas share research development two companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis excluding japan discussion strategic alliance astrazeneca see item financial statementsnote alliances collaborations otsuka simultaneously extension abilify agreement april company otsuka entered oncology agreement sprycel ixempra includes us japan eu markets oncology territory beginning collaboration fees pay otsuka annually following percentages aggregate net sales sprycel ixempra oncology territory net sales million million million million million million billion excess billion periods otsuka contribute first million certain commercial operational expenses relating oncology products oncology territory ii commercial operational expenses relating products oncology territory excess million beginning otsuka copromotes sprycel us japan exercised right copromote top five eu markets beginning january oncology agreement expires respect sprycel ixempra includes changeofcontrol provision acquired abilify agreement described discussion abilfy agreement otsuka see current marketed productsinlicensed discussion strategic alliance otsuka see item financial statementsnote alliances collaborations pfizer company pfizer parties worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered us studied prevention treatment broad range venous arterial thrombotic conditions currently approved marketed eu vte prevention pfizer funds development costs since january fund received million upfront milestone licensing payments pfizer date including million received january could receive additional million pfizer development regulatory milestones met companies jointly develop clinical marketing strategy eliquis share commercialization expenses profits losses equally global basis discussion strategic alliance pfizer see item financial statementsnote alliances collaborations investigational compounds developmentinlicensed lilly january company lilly restructured egfr commercialization agreement provide codevelopment cocommercialization necitumumab imcf fully human antibody currently phase iii development nonsmall cell lung cancer see item managements discussion analysis financial condition results operationsproduct pipeline developments update one phase iii trial restructured companies share cost developing share profits losses upon commercializing necitumumab us canada japan lilly maintains exclusive rights necitumumab markets fund development costs studies used us japan studies global studies pay million lilly milestone payment first approval granted us us canada recognize sales profits losses necitumumab lilly provide selling effort parties general equally participate commercialization efforts japan company lilly share commercial costs profits evenly agreement relates necitumumab continues beyond patent expiration parties agree terminate beginning lilly manufactures bulk requirements assume responsibility fillfinish necitumumab abbott august granted exclusive rights facet biotech corporation abbott codevelopment cocommercialization elotuzumab humanized monoclonal antibody investigated treatment multiple myeloma terms agreement fund development costs elotuzumab upon commercialization abbott share profits losses us paid tiered royalties outside us solely responsible commercialization elotuzumab addition abbott may receive milestone payments us based certain regulatory events sales thresholds achieved investigational compounds developmentinternally discovered astrazeneca mentioned worldwide codevelopment cocommercialization agreement astrazeneca dapagliflozin sglt agreement dapagliflozin studied potential treatment diabetes discovered us sglt agreement received million upfront milestone licensing payments astrazeneca including million received could receive million development regulatory milestones dapagliflozin met additional million salesbased milestones dapagliflozin met majority costs initial plans paid astrazeneca additional development costs generally shared equally except japan astrazeneca bears substantially development costs prior approval first indication expense dapagliflozin development costs net alliance partners share research development sglt agreement like saxagliptin agreement two companies jointly develop clinical marketing strategy share commercialization expenses profits losses dapagliflozin equally global basis manufacture dapagliflozin certain limited exceptions recognize net sales key markets respect japan astrazeneca operational cost responsibility development regulatory activities behalf collaboration related certain trials development costs shared two companies two companies jointly market product japan sharing commercialization expenses activities splitting profits losses equally like rest world also manufacture dapagliflozin recognize net sales japan like rest world dapagliflozin currently studied phase ii clinical trials japan discussion strategic alliance astrazeneca see item financial statementsnote alliances collaborations otsuka january granted otsuka exclusive rights japan develop commercialize onglyza entitled receive milestone payments based certain regulatory events well salesbased payments following regulatory approval onglyza japan retained rights copromote onglyza otsuka japan otsuka responsible development costs japan royalty licensing arrangements addition strategic alliances described inlicensing outlicensing arrangements respect inlicenses agreements novartis reyataz among others based current expectations respect expiration market exclusivity significant markets licensing arrangements novartis reyataz expected expire us eu japan discussion market exclusivity protection including chart showing net sales key products together year basic exclusivity loss occurred expected occur us eu japan canada see products certain compounds outlicensed third parties development commercialization including obtained result acquisitions zymogenetics october medarex august entitled receive milestone payments compounds move regulatory process royalties based product sales products commercialized intellectual property product exclusivity license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan canada certain markets regulatory intellectual property rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives extend market exclusivity period product beyond patent term us eu japan canada also provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy data protection certain markets patent protection forms market exclusivity may expired data protection particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator specific aspects law governing market exclusivity data protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term innovator may depending number factors extend expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical company files new drug application nda medicine biological product biologics license application bla filed type application filed affects regulatory exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file abbreviated nda anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition benefiting patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types regulatory data protection innovative chemical pharmaceutical entitled five years regulatory data protection us competitors file fda approval generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical trials receives three years data protection formulation indication biologic products us healthcare legislation enacted regulatory approval biosimilar versions biological products obtained abbreviated path abbreviated path approval biosimilar products us healthcare legislation significantly affects regulatory data exclusivity biological products legislation provides regulatory mechanism allows fda approval biologic drugs similar generic copies innovative drugs basis less extensive data required full bla legislation created approval pathway biosimilar versions biological products previously exist innovative biological products longer receive essentially unlimited regulatory data exclusivity existed prior creation regulatory path biosimilar versions law innovator marketed biological product four years biosimilar manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation european commission ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities marketing authorization application approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity canada canada medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations currently unlike us canada patent term restoration compensate patent term lost regulatory review process canada biologics generally treated chemicallysynthesized products respect patent rights regulatory exclusivity health canada issued draft guidance outlines additional information provided subsequent entry biologics also known biosimilar products generic biologics order review application marketing approval rest world countries outside us eu japan canada wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu eg switzerland among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well marketing distribution customers promote appropriate use products directly healthcare professionals providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos also provide information appropriate use products consumers us directtoconsumer print radio television advertising addition sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceuticals see government regulation price constraints sales marketing organizations explain approved uses risks benefits products medical professionals work gain access health authorities pbm mco formularies lists recommended approved medicines products including medicare part plans reimbursement lists providing information clinical profile products marketing prescription pharmaceuticals limited approved uses particular product continue develop scientific data information products provide information response unsolicited inquiries doctors medical professionals managed care organizations operations include several marketing sales organizations organization markets distinct group products supported sales force typically based particular therapeutic areas physician groups sales forces often focus selling new products introduced promotion physicians increasingly targeted specialists key primary care physicians products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross sales three largest pharmaceutical wholesalers us percentage total gross sales follows mckesson corporation cardinal health inc amerisourcebergen corporation us business inventory management agreements imas substantially direct wholesaler distributor customers allow us monitor us wholesaler inventory levels requires wholesalers maintain inventory levels one month demand imas expire december subject certain termination provisions number defined markets outside us established full scale distributor model make medically necessary drugs available patients continue marketing authorization trademarks products contracted services fullservice distributor provide distribution logistics regulatory pharmacovigilance sales advertising promotion certain products contracts clearly define terms conditions along services provide supply firm order period monitor inmarket sales forecasts ensure reasonable inventory levels products sale maintained fully continuously meet demand products within distributors territory responsibility sales distributorbased markets represented less companys net sales competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service research development new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products sales also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales generic competition one biggest competitive challenges face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion sales product short period time rate sales decline product expiration exclusivity varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate sales decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity see intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs together ability manufacture products efficiently market effectively highly competitive environment managed care organizations growth mcos us also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical trials demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments particular importance fda us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth oig guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement agency procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda approval approval ema obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us operate environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing markets uk germany government set pricing restrictions launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany companies also face significant delays market access new products mainly france spain italy belgium two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows us internationally healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact net sales march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill legislation makes extensive changes current system healthcare insurance benefits intended broaden coverage reduce costs bills significantly change americans receive healthcare coverage pay also significant impact companies particular companies pharmaceutical industry healthcare related industries including bms experienced continue experience additional financial costs certain changes business new healthcare law implemented example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act also required provide percent discount brandname drugs patients fall within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare many markets outside us operate environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products two years elapse drug approval new medicines become available countries federal state governments also pursued direct methods reduce cost drugs pay participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases programs participate provide discounts outpatient medicines purchased certain specified entities section b public health service act discussion rebates programs see item managements discussion analysis financial condition results operationsnet sales critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance meet expected product demand operate manage manufacturing network including thirdparty contract manufacturers inventory related thereto manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital outofpocket expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing see government regulation price constraints pharmaceutical manufacturing facilities located us puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product line changes next several years expect continue modification existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations february purchased acre site locate large scale multiproduct bulk biologics manufacturing facility devens massachusetts construction devens massachusetts facility began early substantially completed submitted site regulatory approval early expect fda complete review application end year rely third parties manufacture supply us certain active ingredients necessary us manufacture various products including plavix baraclude avalide reyataz abilify erbitux sustiva franchise orencia yervoy onglyza kombiglyze maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted additional protection cases take steps maintain approved backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturers manufacture orencia thirdparty manufacturer rely existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet complex processing requirements biologics business performance prospects could negatively impacted additionally thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain qualityassurance procedures relating quality integrity technical information production processes control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling perform tests various stages production processes final product ensure product meets regulatory requirements standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used us subsidiaries thirdparty suppliers environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis expended approximately million million million capital projects undertaken specifically meet environmental requirements although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees december employed approximately people foreign operations significant operations outside us conducted subsidiaries distributors geographic breakdown net sales see table captioned geographic areas item financial statementsnote business segment information discussion net sales geographic area see item managements discussion analysis financial condition results operationsnet sales international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase decrease reported dollar value net assets results operations change foreign exchange rates net favorable impact growth rate revenues predict certainty future changes foreign exchange rates effect attempt mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnishes material us securities exchange commission sec information relating corporate governance bristolmyers squibb including standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsstockholder services caption incorporate reference certain information parts proxy statement annual meeting stockholders sec allows us disclose important information referring manner please refer information proxy statement annual meeting stockholders annual report available website investorssec filings caption march item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial may also impair operations face intense competition pharmaceutical manufacturers including innovative medicines lowerpriced generic products competition including lowerpriced generic versions products major challenge within us internationally facing patent expirations increasingly aggressive generic competition competition may include new products developed competitors lower prices superior performance safety features otherwise competitive products ii technological advances patents attained competitors iii earlierthanexpected competition generic companies iv clinical study results related products competitors products v business combinations among competitors major customers also could experience limited market access due real perceived differences value propositions products compared competing products depend certain key products net sales cash flows earnings us market exclusivity plavix avaproavalide us expected expire may march respectively derive majority revenue earnings key products net sales plavix approximately billion representing approximately total net sales net sales abilify approximately billion representing approximately total net sales three products reyataz sustiva franchise baraclude billion net sales reduction net sales one key products could significantly negatively impact net sales cash flows earnings plavix topselling product us net sales approximately billion expect plavix loses us exclusivity may rapid precipitous material decline plavix net sales reduction net income operating cash flow avaproavalide us net sales million loses us patent protection march expect experience precipitous decline avaproavalide net sales unable support grow currently marketed products successfully launch newly approved products advance latestage pipeline manage costs effectively loss exclusivity plavix avaproavalide could material negative impact results operations cash flows financial condition possible may lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value usually realized period market exclusivity us countries market exclusivity expires generic versions product approved marketed usually substantial rapid declines products sales rate decline varies country therapeutic category market exclusivity products based upon patent rights andor certain regulatory forms exclusivity scope patent rights may vary country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protection products may exist certain countries historically offer right obtain certain types patents andor licensors file markets absent relevant patent protection product data exclusivity period expires generic versions product approved marketed generic clopidogrel bisulfate certain eu markets addition prior expiration data exclusivity competitor could seek regulatory approval submitting clinical trial data obtain marketing approval manufacturers generic products also increasingly seeking challenge patents expire key patents covering four key products abilify atripla baraclude sprycel currently subject patent litigation cases generic manufacturers may choose launch generic product risk expiration applicable patents andor final resolution related patent litigation length market exclusivity products difficult predict certainty therefore assurance particular product enjoy market exclusivity full period time appears estimates disclosed example unexpectedly lost exclusivity plavix canada face increased pricing pressure restrictions us abroad managed care organizations institutional purchasers government agencies programs could negatively affect net sales profit margins pharmaceutical products continue subject increasing price pressures restrictions us eu regions around world including limited rules practices managed care organizations institutional governmental purchasers ii judicial decisions governmental laws regulations related medicare medicaid us healthcare reform including medicare prescription drug improvement modernization act patient protection affordable care act iii potential impact importation restrictions legislative andor regulatory changes pharmaceutical reimbursement medicare part formularies product pricing general iv delays gaining reimbursement andor reductions reimbursement amounts countries government mandated costcontainment programs eg major european markets japan canada v developments technology andor industry practices could directly indirectly impact reimbursement policies practices thirdparty payers vi limited market access due real perceived differences value propositions products compared competing products business results operations affected continue affected us healthcare reform legislation us described item managements discussion analysis financial condition results operationsexecutive summarybusiness environment patient protection affordable care act hr reconciliation bill containing package changes healthcare bill signed law march bills included provisions reduced net sales increased costs due increased medicaid rebate expanded medicaid program additional prescription drug discounts certain patients medicare part nontaxdeductible annual fee pharmaceutical companies among things continue experience significant financial costs certain changes business implementation us healthcare reform law annual eps impact us healthcare reform increased incremental impact associated medicare part coverage gap annual pharmaceutical company fee us healthcare reform law also created regulatory mechanism allows approval biologic drugs similar generic copies innovative drugs basis less extensive data basis full bla us foreign laws regulations may negatively affect net sales profit margins could become subject new government laws regulations additional healthcare reform initiatives us federal state level countries including additional mandatory discounts ii changes us fda foreign regulatory approval processes may cause delays approving preventing approval new products iii changes corporate tax regulation including part proposed us budget deficit reduction package could include limiting foreign tax credits taxing certain tax havens taxing certain excess income transferring intellectual property limiting disallowing certain us deductions operating interest expenses changing rules earnings repatriations eliminating certain tax credits well changing tax rate phasing currently available tax benefits us certain foreign countries changes tax law iv new laws regulations judicial governmental decisions affecting pricing drug reimbursement receivable repayment access marketing within across jurisdictions v changes intellectual property law vi matters compulsory licenses could alter protections afforded one products legal regulatory changes could negatively affect business operating results financial condition company emerging legislation reduce us federal budget deficit enacted reduce operating results changes product labeling marketed products results certain studies released product approved could potentially negative impact products sales labeling pharmaceutical product changed regulatory authorities time including product market years changes often result additional data postmarketing studies headtohead trials reporting adverse events patients healthcare professionals studies identify biomarkers objective characteristics indicate particular response product therapy studies produce important additional information product new information added products label affect safety risk andor efficacy benefit profile product sometimes additional information studies identifies portion patient population may non responsive medicine labeling changes based studies may limit patient population changes labeling plavix erbitux years ago studies providing additional information may sponsored us also sponsored competitors insurance companies government institutions managed care organizations influential scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population products also negative impact sales product extent patient population product labeling becomes limited additionally certain study results especially headtohead trials could affect products formulary listing could also adversely affect sales may experience difficulties delays manufacturing distribution sale products may experience difficulties delays inherent manufacturing distribution sale products seizure recalls products forced closings manufacturing plants ii supply chain continuity including result natural manmade disaster one facilities critical supplier vendor well failure failure vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays due consolidation rationalization manufacturing facilities sale closure certain sites iv failure sole source single source supplier provide us necessary raw materials supplies finished goods extended period time could impact continuous supply v failure thirdparty manufacturer supply us finished product time vi construction regulatory approval delays related new facilities expansion existing facilities including intended support future demand biologics products vii manufacturing distribution problems including limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations business interruptions could impact continuous supply may experience difficulties delays development commercialization new products may experience difficulties delays development commercialization new products including inherent risks uncertainties developing products compounds products may appear promising development fail reach market within expected optimal timeframe fail ever reach market approved product extensions additional indications number reasons including efficacy safety concerns delay denial necessary regulatory approvals delays difficulties producing products commercial scale level excessive costs manufacture products ii failure enter successfully implement optimal alliances applicable development andor commercialization products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability addition observed recent trend us fda delay approval decision new product beyond announced action date sometimes much six months longer regulatory approval delays especially common product expected risk evaluation mitigation strategy address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could potentially negative impact net sales earnings could result significant impairment inprocess research development intangible assets january bms collaboration partner astrazeneca received complete response letter regarding nda dapagliflozin complete response letter requests additional data allow better assessment benefitrisk profile dapagliflozin includes clinical trial data ongoing studies may require information new clinical trials finally natural manmade disaster sabotage research development labs compound library andor loss key molecules intermediaries could negatively impact product development cycle legal matters adverse outcomes could negatively affect business currently involved could future become involved various lawsuits claims proceedings government investigations could preclude delay commercialization products adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii sales marketing practices us internationally iii adverse decisions litigation including product liability commercial cases iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers may result liability vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection antibribery us foreign corrupt practice act uk antibribery act laws viii environmental health safety matters ix tax liabilities assurance increase scope matters additional lawsuits claims proceedings investigations future assurance matters material adverse impact us rely third parties meet contractual regulatory obligations rely suppliers vendors partners including alliances pharmaceutical companies manufacturing development commercialization products third parties meet contractual regulatory obligations relation arrangements us failure critical third party meet obligations andor development significant disagreements factors materially disrupt ongoing commercial relationship prevent optimal alignment third parties activities could material adverse impact us addition third parties violate alleged violated laws regulations including foreign corrupt practice act performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences dependent outsourcing arrangements dependent thirdparty providers certain outsourced services including certain research development capabilities certain financial outsourcing arrangements certain human resource functions information technology activities systems many thirdparty providers located markets subject political risk corruption infrastructure problems natural disasters addition country specific privacy data security risks given current legal regulatory environments failure service providers meet obligations adequately deploy business continuity plans event crisis andor development significant disagreements natural manmade disasters factors materially disrupt ongoing relationship providers could negatively affect operations failure execute business strategy could adversely impact growth profitability last several years transformed diversified pharmaceutical related healthcare products company biopharmaceutical company focus innovative products areas high unmet medical need focused sustaining business building foundation future plavix largest selling product loses exclusivity us may plan achieve foundation continuing support grow currently marketed products advancing latestage pipeline managing costs maintaining improving financial strength strong balance sheet cash position risks associated strategy may able consistently replenish innovative pipeline internal research development transactions third parties competition among major pharmaceutical companies acquisition product licensing opportunities become intense eliminating opportunities making others expensive may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions additionally changes structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances restructurings strategic initiatives may result greater expected costs may take longer expected complete may encounter difficulties including need regulatory approval appropriate inability expand product portfolio new products maintain competitive cost basis could materially adversely affect future results operations unable support grow currently marketed products successfully execute launches newly approved products advance latestage pipeline manage costs effectively could experience significant material negative impact results operations financial condition addition failure hire retain personnel right expertise experience operations critical business functions could adversely impact execution business strategy increasingly dependent information technology systems infrastructure face certain risks including cybersecurity data leakage risks increasingly dependent information technology systems infrastructure significant breakdown invasion destruction interruption systems employees others authorized access systems unauthorized persons could negatively impact operations also risk could experience business interruption theft information reputational damage result cyber attack infiltration data center data leakage confidential information either internally thirdparty providers invested heavily protection data information technology reduce risks assurance efforts prevent breakdowns breaches systems could adversely affect business expansion social media platforms presents new risks challenges inappropriate use certain media vehicles could cause brand damage information leakage could lead legal implications improper collection andor dissemination personally identifiable information addition negative posts comments us social networking web site could seriously damage reputation disclosure nonpublic company sensitive information external media channels could lead information loss might structured processes place secure protect information identifying new points entry social media continues expand presents new challenges adverse changes us global regional economic conditions could continuing adverse effect profitability businesses high government debt burdens continued high unemployment rates rising prices including related commodities energy lower economic growth adversely affected commercial activity us europe regions world business government austerity measures declines economic activity markets business could adversely affect demand pricing products thus reducing revenues earnings cash flow well passthrough effects us resulting significant financial instability customers distributors alliance partners suppliers critical vendors service providers counterparties certain financial instruments marketable securities derivatives future pension plan funding requirements continue sensitive global economic conditions related impact equity markets changes foreign currency exchange rates interest rates could material adverse effect results operations significant operations outside us revenues operations outside us accounted approximately revenues exposed fluctuations foreign currency exchange rates also borrowings exposed changes interest rates also exposed economic factors control illegal distribution sale third parties counterfeit versions products stolen products could negative impact reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards products undergo patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name addition thefts inventory warehouses plants intransit properly stored sold unauthorized channels could adversely impact patient safety reputation business item b unresolved staff comments none item properties world headquarters located park avenue new york ny lease approximately square feet floor space lease approximately properties countries manufacture products worldwide locations owned us manufacturing locations aggregate square feet floor space geographic area follows december number locations square feet united states europe japan asia pacific canada latin america middle east africa emerging markets total portions manufacturing locations properties owned leased us us elsewhere used research development administration storage distribution information properties see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years lamberto andreotti executive vice president president worldwide chief executive officer director pharmaceuticals division company executive vice member senior management team president chief operating officer worldwide pharmaceuticals division company executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charles bancroft vice president finance worldwide pharmaceuticals executive vice president chief financial officer division company member senior management team chief financial officer company present executive vice president chief financial officer company giovanni caforio md senior vice president us oncology worldwide president us pharmaceuticals pharmaceuticals division company member senior management team senior vice president oncology global commercialization senior vice president oncology immunoscience global commercialization present president us pharmaceuticals joseph c caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller beatrice cazala president emea worldwide medicines international executive vice president commercial operations president emea asia pacific worldwide medicines member senior management team international president global commercialization president europe senior vice president commercial operations president global commercialization europe emerging markets present executive vice president commercial operations john e celentano president health care group division company senior vice president human resources public senior vice president strategy productivity affairs philanthropy transformation member senior management team president emerging markets asia pacific present senior vice president human resources public affairs philanthropy francis cuss mb bchir frcp senior vice president discovery exploratory clinical senior vice president research development development member senior management team present senior vice president research research development brian daniels md senior vice president global clinical development research senior vice president global development development division company medical affairs research development present senior vice president global development medical member senior management team affairs research development sandra leung vice president corporate secretary acting general general counsel corporate secretary counsel member senior management team present general counsel corporate secretary louis schmukler senior vice president pharmaceutical operating unit wyeth president technical operations senior vice president specialtybiotechnology operating member senior management team unit pfizer present president technical operations elliott sigal md phd executive vice president chief scientific officer president executive vice president chief scientific officer research development president research development director present executive vice president chief scientific officer member senior management team president research development director company paul von autenried vice president chief information officer senior vice president chief information officer present senior vice president chief information officer member senior management team part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange nyse symbol bmy quarterly summary high low market prices presented high low high low common first quarter second quarter third quarter fourth quarter preferred first quarter second quarter third quarter fourth quarter first third fourth quarters third quarter observable trades companys preferred stock holders common stock number record holders common stock december number record holders based upon actual number holders registered books date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies dividends board directors declared following dividends per share paid quarters indicated common preferred first quarter second quarter third quarter fourth quarter december board directors declared quarterly dividend per share common stock paid february shareholders record january board directors also declared quarterly dividend per share preferred stock payable march shareholders record february issuer purchases equity securities following table summarizes surrenders repurchases equity securities month period ended december total number shares approximate dollar value average price purchased part shares may yet total number paid publicly announced purchased period shares purchaseda per sharea plans programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations b may announced board directors authorized purchase billion common stock repurchase program expiration date expected take place years item selected financial data five year financial summary amounts millions except per share data income statement dataa net sales continuing operations net earnings net earnings attributable noncontrolling interest net earnings attributable bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted dividends paid bms common preferred stock dividends declared per common share financial position data december cash cash equivalents marketable securitiesb total assets longterm debt equity discussion items affected comparability results years see item managements discussion analysis financial condition results operationsnon gaap financial measures b marketable securities include current noncurrent assets item managements discussion analysis financial condition results operations executive summary bristolmyers squibb company may referred bristolmyers squibb bms company us global biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases license manufacture market distribute sell pharmaceutical products global basis continued execute stringofpearls strategy acquisition amira pharmaceuticals inc amira september inhibitex inc inhibitex february various collaboration agreements entered year yervoy ipilimumab launched united states us european union eu treatment adult patients unresectable inoperable metastatic melanoma also launched subcutaneous formulation orencia abatacept us nulojix belatacept us eu prevention organ rejection adult patients receiving kidney transplant eliquis apixaban eu prevention venous thromboembolic events vte adult patients undergone hip knee replacement surgery announced main results aristotle trial eliquis compared warfarin significantly reduced risk stroke systemic embolism new drug application nda us marketing authorization application maa eu eliquis accepted review january received complete response letter us food drug administration fda regarding nda dapagliflozin complete response letter requests additional clinical data ongoing studies may require information new clinical trials highlights following table summary financial highlights year ended december dollars millions except per share data net sales total expenses earnings continuing operations income taxes provision income taxes effective tax rate net earnings continuing operations attributable bms gaap nongaap diluted earnings per share continuing operations attributable bms gaap nongaap cash cash equivalents marketable securities nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures see nongaap financial measures business environment business primarily conducted within pharmaceuticalbiotechnology industry highly competitive subject numerous government regulations many competitive factors may significantly affect sales products including product efficacy safety price demand competition cost effectiveness marketing effectiveness market access product labeling quality control quality assurance manufacturing operations research development new products successfully compete business healthcare industry must demonstrate products offer medical benefits well cost advantages sometimes new product introductions compete products already market therapeutic category addition potential competition new products competitors may introduce future manufacture branded products priced higher generic products generic competition one leading challenges globally pharmaceuticalbiotechnology industry majority innovative products commercial value usually realized market exclusivity period afterwards longer protected patent subject new competing products form generic brands upon exclusivity loss lose major portion products sales short period time competitors seeking approval biological products full biologics license application bla must file safety efficacy data address challenges biologics manufacturing involve complex processes costly pharmaceutical operations us healthcare legislation enacted described fully abbreviated path regulatory approval generic versions biological products path approval biosimilar products us healthcare legislation significantly affects regulatory data exclusivity biological products legislation provides regulatory mechanism allows regulatory approval biologic drugs similar generic copies innovative drugs basis less extensive data required full bla possible time reasonably assess impact us biosimilar legislation company globally healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact net sales march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill legislation made extensive changes healthcare insurance benefits system intention broadening coverage reducing costs bills significantly changed americans receive healthcare coverage pay also significant impact companies particular companies pharmaceutical industry healthcare related industries including bms experienced continue experience additional financial costs certain changes business healthcare law provisions become effective example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans two additional provisions impact financial results went effect january first percent discount brandname drugs patients within medicare part coverage gap also referred donut hole second annual nontaxdeductible pharmaceutical company fee payable federal government based allocation market share branded prior year sales certain us government programs including medicare medicaid department veterans affairs department defense tricare annual eps impact us healthcare reform increased net sales reduced million resulting new discounts associated medicare part coverage gap marketing selling administrative expenses increased million due new annual non taxdeductible pharmaceutical company fee incremental impact associated medicare part coverage gap annual pharmaceutical company fee aggregate financial impact us healthcare reform next years depends number factors including limited pending implementation guidance potential changes sales volume eligible new rebates discounts fees impact cost sharing arrangements certain alliance partners positive impact net sales expected increase number people healthcare coverage could potentially occur future expected earliest many markets outside us operate environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system many european countries continuing fiscal challenges healthcare payers including government agencies reduced expected continue reduce cost healthcare actions directly indirectly impose additional price restrictions companies also face significant delays market access new products two years elapse drug approval new medicines become available countries growth managed care organizations mcos us significantly impacted competition surrounds healthcare industry mcos seek reduce healthcare expenditures participants making volume purchases entering longterm contracts negotiate discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos become important part strategy companies compete inclusion mco formularies generally successful key products included believe developments managed care industry including continued consolidation continue downward pressure prices pharmaceutical biotechnology production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become larger percentage product portfolio continue make supply arrangements thirdparty manufacturers make substantial investments increase internal capacity produce biologics commercial scale one investment new stateoftheart manufacturing facility production biologics devens massachusetts submitted site regulatory approval expect fda complete review application end year maintained competitive position market strive uphold position dependent success discovering developing delivering innovative costeffective products help patients prevail serious diseases subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcomes investigations litigations additional discussion legal matters see item financial statementsnote legal proceedings contingencies strategy past years transformed company focused biopharmaceutical company transformation encompasses areas business operations focused portfolio products yielded continue yield substantial cost savings cost avoidance turn increases financial flexibility take advantage attractive market opportunities may arise may expect lose exclusivity us largest product plavix time expect rapid precipitous material decline plavix net sales reduction net income operating cash flow also expect decline avaproavalide irbesartanirbesartan hydrochlorothiazide net sales immediately following loss exclusivity us march events norm industry companies experience loss exclusivity product recognizing fact continue focus sustaining business building robust foundation future plan achieve foundation continuing support grow currently marketed products advancing pipeline maintaining improving financial strength part overall strategy build company continue expand biologics capabilities still rely significantly small molecules strongest reliable starting point discovering potential new medicines large molecules biologics derived recombinant dna technologies becoming increasingly important currently one three pipeline compounds biologics four key marketed products including yervoy strategy also includes focus certain emerging markets acquisition licensing strategy known stringofpearls optimizing mature brands portfolio managing costs strategy emerging markets develop commercialize innovative products key highgrowth markets tailoring approach market continuing focus core biopharmaceuticals maximizing value mature brands portfolio completed following strategic transactions acquired amira pharmaceutical inc amira smallmolecule pharmaceutical company focused fibrotic disease entered agreement ono pharmaceuticals co ltd ono expand territorial rights develop commercialize antibody pd investigational cancer immunotherapy create strategic alliance codevelopment cocommercialization orencia japan obtained exclusive worldwide rights ambrx inc ambrx research develop commercialize novel biologics diabetes heart disease obtained exclusive worldwide rights innate pharma sa innate develop commercialize iph novel immuneoncology biologic phase development entered clinical collaboration roche evaluate utility yervoy combination roches investigational braf inhibitor vermurafenib treating patients specific type metastatic melanoma announced licensing agreement gilead sciences inc gilead development commercialization new fixeddose combination containing reyataz gileads cobicistat treatment hiv entered strategic partnership aslan pharmaceuticals development bms investigational small molecule inhibitor met receptor tyrosine kinase treatment solid tumors entered clinical collaboration agreement tibotec pharmaceuticals tibotec one janssen pharmaceutical companies evaluate utility daclatasvir bms investigational nsa replication complex inhibitor combination tibotecs investigational ns protease inhibitor tmc treatment chronic hepatitis c virus agreed codevelop bms preclinical small molecule inhibitor cholesteryl ester transfer protein cetp could potentially raise hdl good cholesterol levels help prevent cardiovascular disease simcere pharmaceutical group simcere entered clinical collaboration pharmasset inc pharmasset wholly owned subsidiary gilead evaluate utility declatasvir bms nsa replication complex inhibitor combination psi pharmassets nucleotide polymerase inhibitor treatment chronic hepatitis c virus subsequently announced addition four additional treatment arms phase iia trial february acquired inhibitex inc inhibitex clinicalstage biopharmaceutical company focused developing products treat hepatitis c virus serious infectious diseases product pipeline developments manage research development rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth consider rd programs entered phase iii development significant programs constitute latestage development pipeline phase iii development programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations spending programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years expect latestage development programs make market latestage development programs rd programs could potentially impact revenue earnings within next years following recent significant developments marketed products latestage pipeline yervoy monoclonal antibody treatment patients unresectable inoperable metastatic melanoma currently also studied indications including lung cancer well adjuvant melanoma hormonerefractory prostate cancer july company announced european commission approved yervoy treatment adult patients previouslytreated advanced melanoma june company announced th annual meeting american society clinical oncology results study evaluated newlydiagnosed patients treated yervoy mgkg combination dacarbazine versus dacarbazine alone significant improvement overall survival patients treated yervoy plus dacarbazine versus received dacarbazine alone higher estimated survival rates observed one year two years three years patients treated yervoy plus dacarbazine versus received dacarbazine alone june company announced entered clinical collaboration roche evaluate utility yervoy combination roches investigational braf inhibitor vermurafenib treating patients specific type metastatic melanoma march fda approved yervoy treatment patients newly diagnosed previouslytreated unresectable inoperable metastatic melanoma eliquis oral factor xa inhibitor indicated eu prevention venous thromboembolic events vte adult patients undergone elective hip knee replacement surgery development stroke prevention patients atrial fibrillation af prevention treatment venous thromboembolic disorders part strategic alliance pfizer inc pfizer november fda accepted review nda eliquis prescription drug user fee act pdufa goal date decision fda march also validated application eu november company pfizer announced results phase iii adopt trial evaluated eliquis versus enoxaparin acutely ill medical patients meet primary efficacy outcome superiority enoxaparin endpoint vte vterelated deaths august european society cardiology congress company pfizer announced main results phase iii aristotle trial evaluated eliquis compared warfarin prevention stroke systemic embolism patients atrial fibrillation least one risk factor stroke eliquis compared warfarin significantly reduced risk stroke systemic embolism percent major bleeding percent mortality percent june company pfizer announced phase iii aristotle trial eliquis met primary efficacy objective noninferiority warfarin combined outcome stroke ischemic hemorrhagic unspecified type systemic embolism addition eliquis met key secondary endpoints superiority efficacy international society thrombosis haemostasis isth major bleeding compared warfarin may company pfizer announced european commission approved eliquis prevention vte adult patients undergone elective hip knee replacement surgery february company pfizer published full results averroes study eliquis new england journal medicine study demonstrated patients af expected demonstrated unsuitable vitamin k antagonist therapy warfarin eliquis statistically superior aspirin reducing composite stroke systemic embolism without significant increase major bleeding fatal bleeding intracranial bleeding significant differences risk hemorrhagic stroke eliquis aspirin study results also showed eliquis demonstrated superiority secondary efficacy endpoint reducing composite stroke systemic embolism myocardial infarction vascular death patients af compared aspirin nulojix fusion protein novel immunosuppressive activity prevention kidney transplant rejection june company announced fda european commission approved nulojix prophylaxis organ rejection adult patients receiving kidney transplant new data nulojix presented american transplant congress european society organ transplantation esot meeting including threeyear outcomes benefit phase iii study nulojix vs cyclosporine kidney transplant recipients ii threeyear safety profile nulojix kidney transplant recipients benefit benefitext studies iii renal function two years kidney transplant recipients switched cyclosporine tacrolimus nulojix results longterm extension phase ii study iv threeyear outcomes donor type phase iii studies nulojix vs cyclosporine kidney transplantation benefit benefitext dapagliflozin oral sglt inhibitor treatment diabetes part strategic alliance astrazeneca plc astrazeneca january fda issued complete response letter regarding nda dapagliflozin complete response letter requests additional clinical data allow better assessment benefitrisk profile dapagliflozin includes clinical trial data ongoing studies may require information new clinical trials companies work closely fda determine appropriate next steps dapagliflozin application ongoing discussions health authorities europe countries part application procedures december company astrazeneca announced international diabetes federation world diabetes conference results phase iii study dapagliflozin showed reductions blood sugar levels glycosylated hemoglobin levels hbac seen weeks dapagliflozin existing glimepiride sulfonylurea therapy compared placebo added glimepiride maintained weeks adults type diabetes patients taking dapagliflozin added glimepiride also maintained reductions fasting plasma glucose levels postprandial glucose total body weight november company astrazeneca presented metaanalysis clinical data cardiovascular safety adult patients type diabetes showed dapagliflozin associated unacceptable increase cardiovascular risk relative comparators pooled clinical programs july fdas endocrinologic metabolic drugs advisory committee voted nine six efficacy safety data provide substantial evidence support approval nda dapagliflozin adjunct diet exercise improve glycemic control adults type diabetes mellitus june american diabetes association meeting company astrazeneca presented results several phase iii clinical studies examining dapagliflozin added metformin maa dapagliflozin validated ema maa submission dapagliflozin filed december orencia fusion protein indicated rheumatoid arthritis november american college rheumatology annual scientific meeting company presented new data orencia clinical trials support recent fda approval subcutaneous formulation orencia reduction signs symptoms adults moderate severe arthritis data presented included longterm immunogenicity data intravenous formulation longterm safety data rheumatoid arthritis results phase iiiii study lupus nephritis august maa subcutaneous formulation orencia validated review european medicine agency july fda approved subcutaneous formulation orencia treatment adults moderate severe rheumatoid arthritis onglyzakombiglyze saxagliptinsaxagliptin metformin treatment type diabetes part strategic alliance astrazeneca december fda approved onglyza use combination therapy insulin without metformin improve blood sugar adult patients type diabetes november european commission approved kombiglyze known eu komboglyze treatment type diabetes november european commission approved onglyza use combination therapy insulin without metformin improve blood sugar glycemic control adult patients type diabetes september th european association study diabetes annual meeting company astrazeneca announced results investigational phase iiib clinical study reported onglyza mg added insulin without metformin maintained glycemic control glycosylated hemoglobin levels hbac adult patients type diabetes compared addition placebo weeks june company astrazeneca announced results investigational phase iiib clinical study reported onglyza mg added insulin without metformin significantly reduced blood sugar levels glycosylated hemoglobin levels hbac weeks compared treatment placebo added insulin without metformin may company astrazeneca announced state food drug administration approved onglyza china february company astrazeneca announced european commission approved label update onglyza treatment adults type diabetes moderate severe renal impairment making onglyza first dipeptidyl peptidase ddp inhibitor europe available type diabetes patients moderate severe renal impairment february company astrazeneca announced fda approved inclusion data two clinical studies update onglyza us prescribing information adults type diabetes us label update provides evidence regarding use renally impaired adults type diabetes well comparisons glipizide onglyza patients also taking metformin sprycel dasatanib oral inhibitor multiple tyrosine kinases indicated treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate firstline treatment adults sprycel part strategic alliance otsuka pharmaceuticals inc otsuka september chinas state food drug administration approved sprycel treatment adults chronic accelerated lymphoid myeloid chronic myeloid leukemia resistance intolerance prior therapy imatinib june regulatory authorities japan approved use sprycel firstline treatment chronic myeloid leukemia june company otsuka announced fiveyear follow data sprycel mg daily demonstrated overall survival patients chronicphase myeloid leukemia resistant intolerant gleevec results announced th annual meeting american society clinical oncology plavix platelet aggregation inhibitor part alliance sanofi january company sanofi announced fda granted companies additional sixmonth period exclusivity market plavix exclusivity plavix us scheduled expire may baraclude entecavir oral antiviral agent treatment chronic hepatitis b november nd annual meeting american association study liver disease company announced results week study phase iiib clinical trial showed statistical difference baraclude monotherapy mg daily baraclude mg daily plus tenovir mg daily treatmentnave adult patients hbeagpositive hbeagnegative chronic hepatitis b compensated liver disease february european commission approved baraclude treatment hepatitis b adult patients decompensated liver disease abilify aripiprazole antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part strategic alliance otsuka february company otsuka announced fda approved abilify adjunct mood stabilizers lithium valproate maintenance treatment bipolar disorder european approval use received january reyataz atazanavir sulfate protease inhibitor treatment hiv february fda approved update labeling reyataz include dose recommendations hivinfected pregnant women hiv combination therapy treatment recommended adult dose reyataz mg boosted mg ritonavir achieved minimum plasma concentrations hours postdose third trimester pregnancy comparable observed historically hivinfected adults post partum period atazanavir concentrations may increased therefore dose adjustment necessary patients monitored two months delivery erbitux cetuximab monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part alliance eli lilly company lilly november fda approved erbitux combination platinumbased chemotherapy fluorouracil first line treatment recurrent locoregional metastatic squamous cell carcinoma head neck necitumumab imcf investigational anticancer agent part strategic alliance lilly february company lilly announced enrollment stopped phase iii inspire study necitumumab firstline treatment advanced nonsmall cell lung cancer trial evaluating addition necitumumab combination alimta pemetrexed injection cisplatin decision stop enrollment followed independent data monitoring committee dmc recommendation new recently enrolled patients continue treatment trial safety concerns related thromboembolism experimental arm study dmc also noted patients already received two cycles necitumumab appear lower ongoing risk safety concerns patients could choose remain trial informed additional potential risks investigators continue assess patients two cycles determine potential benefit treatment necitumumab continues studied another phase iii trial named squire study evaluating necitumumab potential treatment different type lung cancer called squamous nonsmall cell lung cancer combination gemzar gemcitabine hcl injection cisplatin independent dmc recommended trial continue safety concerns observed brivanib investigational anticancer agent january american society clinical oncology asco gastrointestinal cancers symposium national cancer institute canada ncic clinical trials group australasian gastrointestinal trials group agitg presented results phase iii randomized trial cetuximab plus either brivanib alaninate placebo patients metastatic chemotherapy refractory kras wild type colorectal carcinoma primary endpoint improvement overall survival met trial december company reported phase iii briskps brivanib study hcc patients risk post sorafenib clinical trial patients hepatocellular carcinoma hcc liver cancer failed intolerant sorafenib meet primary endpoint improving overall survival versus placebo results operations net sales composition changes net sales follows year ended december vs vs net sales analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange united states europe japan asia pacific canada latin america middle east africa emerging markets na na na na total total sales growth periods attributable higher volume higher average net selling prices favorable foreign exchange reflects continued growth key products offset declines sales avaproavalide mature brands across regions international sales plavix change us net sales attributed price result higher average net selling prices plavix periods abilify partially offset reduction contractual share abilify net sales reduction higher rebates discounts resulting us healthcare reform legislation change us net sales attributed volume reflects recent launch yervoy increased demand several key products partially offset decreased prescription demand avaproavalide plavix expect continue decrease result expected loss exclusivity products change us net sales attributed volume reflects increased demand several key products see key products discussion sales key product net sales europe increased due favorable foreign exchange sales growth key products partially offset lower sales certain mature brands divestitures generic competition well generic competition plavix avaproavalide net sales europe decreased due unfavorable foreign exchange previously mentioned generic competition offset sales growth key products net sales periods negatively impacted continuing fiscal challenges many european countries healthcare payers including government agencies reduced expected continue reduce cost healthcare actions directly indirectly impose additional price reductions measures include limited mandatory discounts rebates price reductions restrictive measures net sales japan asia pacific canada increased periods primarily due higher demand baraclude sprycel net sales also increased recent launch orencia japan approval sprycel first line indication japan impacts partially offset generic competition avaproavalide canada lower sales mature brands generic competition divestitures periods emerging markets region comprised brazil russia india china turkey net sales growth periods driven increased sales volume primarily china brazil partially offset pricing pressures turkey russia higher net sales china primarily attributable baraclude certain mature brands periods higher net sales brazil primarily attributable reyataz abilify single country outside us contributed total net sales general business seasonal information us pharmaceutical prescriber demand reference made table within estimated enduser demand sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain key products us nonus net sales categorized based upon location customer recognize revenue net grosstonet sales adjustments described critical accounting policies contractual share abilify atripla sales reflected net grosstonet sales adjustments gross sales reconciliation gross sales net sales significant category grosstonet sales adjustments follows year ended december dollars millions gross sales grosstonet sales adjustments chargebacks related government programs cash discounts managed healthcare rebates contract discounts medicaid rebates sales returns adjustments total grosstonet sales adjustments net sales activities ending balances significant category grosstonet sales reserve adjustments follows managed healthcare chargebacks rebates related government cash contract medicaid sales dollars millions programs discounts discounts rebates returns adjustments total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december grosstonet sales adjustments percentage worldwide gross sales primarily function gross sales trends changes sales mix contractual legislative discounts rebates grosstonet sales adjustments increased due chargebacks related government programs increased periods primarily due reimbursements price increases excess current inflation rates us managed healthcare rebates contract discounts increased due discount patients within medicare part coverage gap medicaid rebates increased due change minimum rebates drug sales extension medicaid rebate rate drugs sold riskbased medicaid managed care organizations medicaid rebates continued increase due full year impact expansion medicaid rebates drugs used riskbased medicaid managed care plans higher average net selling prices plavix higher medicaid channel sales increase unpaid rebates due part timing increasing lag payments attributed government agencies administrative delays sales returns included million reduction million us return reserve established connection recall certain lots avalide due lower returns expected sales returns attributable sales expected increase result loss exclusivity plavix avaproavalide key products net sales key products represented total net sales following table presents us international net sales key product percentage change prior period foreign exchange impact compared prior period commentary detailing reasons significant variances key products provided change attributable year ended december change foreign exchange dollars millions vs vs vs vs key products plavix clopidogrel bisulfate us nonus avaproavalide irbesartanirbesartanhydrochlorothiazide us nonus abilify aripiprazole us nonus reyataz atazanavir sulfate us nonus sustiva efavirenz franchise us nonus baraclude entecavir us nonus erbitux cetuximab us nonus sprycel dasatinib us nonus yervoy ipilimumab na na na na na na us na na na na na na nonus na na na na na na orencia abatacept us nonus nulojix belatacept na na na na na na us na na na na na na nonus na na na na na na onglyzakombiglyze saxagliptinsaxagliptin metformin us nonus mature products us nonus change excess plavix platelet aggregation inhibitor part alliance sanofi us net sales increased periods primarily due higher average net selling prices estimated total us prescription demand decreased respectively expect rapid material decline plavix sales following loss exclusivity may plavix sales depend erosion rates generic competition wholesale retail inventory levels expected returns international net sales continue impacted launch generic clopidogrel products eu australia negative impact net sales eu comarketing countries australia equity net income affiliates relates share sales partnership sanofi europe asia expect continued erosion plavix net sales eu impact international net sales equity net income affiliates also expect erosion international net sales following recent loss exclusivity plavix canada see item financial statementsnote legal proceedings contingenciesplavix litigation discussion plavix exclusivity litigation us eu avaproavalide known eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy also part sanofi alliance us net sales decreased due market share losses subsequent avalide supply shortage first quarter associated previously reported recalls total estimated us prescription demand decreased decrease us net sales partially offset higher average net selling prices reduction previously established reserves estimated returns connection recall certain lots avalide due lower actual returns expected expect rapid material decline avaproavalide sales following loss exclusivity march international net sales decreased due lower demand including generic competition certain eu markets canada us international net sales decreased primarily due decreased overall demand due generic competition eu reduced supply avalide addition million sales return adjustment recorded result avalide recall estimated total us prescription demand decreased eliquis oral factor xa inhibitor prevention vte adult patients undergone elective hip knee replacement surgery development prevention treatment venous thromboembolic disorders stroke prevention patients atrial fibrillation part strategic alliance pfizer eliquis approved eu vte prevention may launched limited number eu countries beginning may net sales less million abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part strategic alliance otsuka us net sales increased due higher overall demand average net selling prices partially offset reduction contractual share net sales estimated total us prescription demand increased us net sales decreased primarily due reduction contractual share net sales higher medicaid rebates healthcare reform decrease partially offset higher average net selling prices overall demand estimated total us prescription demand increased periods international net sales increased due higher demand reyataz protease inhibitor treatment hiv us net sales relatively flat increased primarily due higher demand estimated total prescription demand increased periods international net sales increased primarily due higher demand sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sold joint venture gilead us net sales increased primarily due higher average net selling prices higher estimated total us prescription demand us net sales increased primarily due higher estimated total us prescription demand periods international net sales increased primarily due higher demand baraclude oral antiviral agent treatment chronic hepatitis b net sales periods increased primarily due higher demand erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part strategic alliance lilly sold us almost exclusively us net sales increased primarily due higher demand including demand approval erbitux firstline treatment recurrent locally regionally advanced metastatic squamous cell carcinoma head neck net sales decreased primarily due lower demand lower average net selling prices sprycel oral inhibitor multiple tyrosine kinases indicated treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel part strategic alliance otsuka net sales periods increased primarily due higher demand average net selling prices demand positively impacted approval sprycel firstline treatment adult patients newly diagnosed philadelphia chromosomepositive chronic myeloid leukemia chronic phase us eu fourth quarter yervoy monoclonal antibody treatment patients unresectable inoperable metastatic melanoma yervoy launched us second quarter limited number eu countries third fourth quarters net sales million deferred patient infusion due returns policy established third quarter us orencia fusion protein indicated adult patients moderate severe rheumatoid arthritis inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy us net sales increased periods primarily due higher demand including launch orencia subcutaneous formulation higher average net selling prices international net sales increased periods primarily due higher demand nulojix fusion protein novel immunosuppressive activity targeted prevention kidney transplant rejection nulojix approved launched us eu onglyzakombiglyze treatment type diabetes onglyzakombiglyze increased periods primarily due higher overall demand launches various countries kombiglyze launched us fourth quarter mature products includes products lost exclusivity major markets counter brands international net sales decreased due continued generic erosion certain products lower average net selling prices europe year year impact rationalization divestitures nonstrategic product portfolio lower demand certain counter products estimated us prescription change data provided throughout report includes information retail mail order channels reflect product demand within channels hospitals home health care clinics federal facilities including veterans administration hospitals longterm care among others data provided wolters kluwer health wk except sprycel based source prescription audit december sprycel demand based upon information nextgeneration prescription service ngps version national prescription audit provided ims health ims data product respective service providers recordkeeping projection processes therefore subject inherent limitations estimates based sampling may include margin error prior december sprycel demand calculated based upon data obtained ims health ims national sales perspectives audit since management believes information ims national prescription audit accurately reflects subscriber demands trends versus pill data ims national sales perspectives audit prior year sprycel data restated reflect information ims national prescription audit continuously seek improve quality estimates prescription change amounts ultimate patientconsumer demand reviewing calculation methodologies employed analyzing internal thirdparty data expect continue review refine methodologies processes calculation estimates monitor quality third parties data used calculations calculated estimated total us prescription change weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions mail order prescriptions typically reflect day prescription whereas retail prescriptions typically reflect day prescription calculation derived multiplying mail order prescription data factor approximates three adding retail prescriptions believe calculation estimated total us prescription change based weightedaverage approach provides superior estimate total prescription demand retail mail order channels use methodology internal demand reporting estimated enduser demand following tables set forth key products sold us years ended december change reported us net sales year ii estimated total us prescription change retail mail order channels calculated us based thirdparty data weightedaverage basis iii months inventory hand wholesale distribution channel year ended december december change us change us months net sales total prescriptions hand dollars millions plavix avaproavalide abilify reyataz sustiva franchisea baraclude erbituxb na na na sprycel yervoybc na na na na na na na na orenciab na na na nulojixbc na na na na na na na na onglyzakombiglyzed na na sustiva franchise total revenue includes sales sustiva revenue bulk efavirenz included combination therapy atripla months hand relates sustiva b erbitux yervoy orencia nulojix parenterally administered products prescriptionlevel data physicians write prescriptions products c yervoy nulojix launched us second quarter onglyza launched us third quarter kombiglyze launched us fourth quarter onglyza month inventory hand december kombiglyze months inventory hand december support initial product launch change excess pursuant us securities exchange commission sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand products material dates indicated us products estimated levels inventory distribution channel excess one month hand december international products estimated levels inventory distribution channel excess one month hand september nulojix months inventory hand us support initial product launch inventory nominal expected worked less amount time demand new product increases post launch dafalgan analgesic product sold principally europe months inventory hand direct customers compared months inventory hand december level inventory hand primarily due ordering patterns pharmacists france fervex cold flu product months inventory hand internationally direct customers compared months inventory hand december level inventory hand decreased due higher demand france russia luftal antacid product months inventory hand internationally direct customers compared months inventory hand december level inventory hand primarily due government purchasing patterns brazil us products sold exclusively wholesalers distributors generally determined months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products provided distributors factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes businesses outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available developed variety methodologies estimate data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly rely variety methods estimate direct customer product level inventory calculate months hand factors may affect estimates include generic competition seasonality products direct customer purchases light price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses net sales change vs vs cost products sold marketing selling administrative advertising product promotion research development provision restructuring litigation expense net equity net income affiliates incomeexpense total expenses change excess cost products sold cost products sold consists material costs internal labor overhead owned manufacturing sites thirdparty processing costs supply chain costs settlement foreign currency forward contracts used hedge forecasted intercompany inventory purchase transactions essentially costs managed primarily global manufacturing organization referred technical operations discovery royalties attributed licensed products connection alliances profit sharing payments certain collaborations amortization acquired developed technology costs business combinations milestone payments occur regulatory approval also included cost products sold cost products sold vary periods result product mix particularly resulting royalties profit sharing expenses connection alliances price inflation costs attributed rationalization manufacturing sites resulting accelerated depreciation impairment charges stranded costs addition changes foreign currency may also provide volatility given high percentage total costs denominated foreign currencies increase cost products sold periods primarily attributable higher sales volume resulting additional royalties collaboration fees profit sharing expense unfavorable foreign exchange cost products sold percentage net sales reflected favorable product mix marketing selling administrative marketing selling administrative expenses consist salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs expenses attributed product manufacturing costs research development expenses expenses managed regional commercialization functions global functions finance law information technology human resources increase primarily attributed annual pharmaceutical company fee million unfavorable foreign exchange higher marketing costs support new launches key products lesser extent higher bad debt expense eu charitable funding information technology expenses decrease primarily attributed reduction sales related activities certain key products coincide respective life cycle prior year impact million funding payment made bms foundation reduction abilify sales force otsuka established sales force promotion abilify sprycel ixempra reduced project standardization implementation costs role new accounting human resource related systems overall efficiencies gained continuous improvement initiatives advertising product promotion advertising product promotion expenses consist related media sample direct consumer programs decrease primarily attributed lower spending promotion certain key products coincide product life cycle otsukas reimbursement certain abilify sprycel ixempra advertising product promotion expenses partially offset increased spending onglyza launch pipeline products research development research development expenses consist salary benefit costs thirdparty grants fees paid clinical research organizations supplies facility costs total research development expenses include costs discovery research preclinical development early lateclinical development drug formulation well clinical trials medical support marketed products proportionate allocations enterprisewide costs appropriate costs expenses also include thirdparty licensing fees typically paid upfront well regulatory contractual milestones met certain expenses shared alliance partners based upon contractual agreements expenses managed global research development organization approximately billion total spend attributed development activities remainder attributed preclinical research activities expenses vary periods number reasons including timing upfront milestone licensing payments increase attributed higher upfront milestone licensing payments unfavorable foreign exchange additional development costs resulting acquisition zymogenetics upfront milestone licensing payments million included million payment associated amendment intellectual property license agreement yervoy prior fda approval payments abbott laboratories abbott innate ambrx alder biopharmaceuticals inc alder nissan chemical industries ltd teijin pharma limited nissan teijin exclusive licenses develop commercialize certain programs compounds decrease attributed lower upfront milestone licensing payments partially offset additional spending support maturing pipeline compounds obtained stringofpearls strategy upfront milestone licensing payments million primarily attributed exelixis allergan inc abbott million primarily attributed zymogenetics alder nissan teijin provision restructuring provision restructuring primarily attributable employee termination benefits continuous improvement initiatives litigation expense net amount primarily due million securities litigation settlement equity net income affiliates equity net income affiliates primarily related international partnership sanofi varies based international plavix net sales included within partnership decrease attributed impact alternative salt form clopidogrel generic clopidogrel competition international plavix net sales commenced additional information see item financial statementsnote alliances collaborations incomeexpense incomeexpense include year ended december dollars millions interest expense interest income impairment loss sale manufacturing operations gain sale product lines businesses assets income received alliance partners pension curtailment settlement charges litigation chargesrecoveries product liability charges recoveries incomeexpense impairment loss sale manufacturing operations primarily attributed disposal manufacturing operations latina italy gain sale product lines businesses assets primarily related sale mature brands including businesses within indonesia australia income alliance partners includes income earned sanofi partnership amortization certain upfront milestone licensing payments related alliances pension curtailment settlement charges primarily attributed amendments eliminated crediting future benefits related service us pension plan participants amendments resulted curtailment charge million million respectively remainder charges resulted lump sum payments certain plans exceeded sum plan interest costs service costs resulting acceleration portion previously deferred actuarial losses additional charges may recognized future particularly us pension plans due lower threshold resulting elimination service costs potentially higher lump sum payments see item financial statementsnote pension postretirement postemployment liabilities detail product liability charges additional reserves connection breast implant settlement program hormone replacement therapy products nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items due significant andor unusual nature evaluated individual basis items excluded segment income similar charges gains items recognized prior periods reasonably possible could reoccur future periods nongaap information intended portray results baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical products global basis enhance investors overall understanding past financial performance prospects future example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap specified items follows year ended december dollars millions except per share data cost products sold process standardization implementation costs bms foundation funding initiative marketing selling administrative upfront milestone licensing payments iprd impairment research development provision restructuring litigation expense recoveries impairment loss sale manufacturing operations gain sale product lines businesses assets pension curtailment settlement charges acquisition related items litigation chargesrecoveries product liability chargesrecoveries loss sale investments debt repurchase upfront milestone licensing receipts incomeexpense decrease pretax income income tax items outof period tax adjustment specified tax benefitcharge income taxes decrease net earnings specified items included cost products sold include accelerated depreciation asset impairment shutdown costs specified tax benefit relates releases tax reserves specified prior periods specified tax charge relates tax charge additional us taxable income earnings foreign subsidiaries previously considered permanently reinvested offshore reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bmsgaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculationgaap net earnings attributable bmsgaap less specified items net earnings attributable bmsnongaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculationnongaap average common shares outstandingdiluted diluted eps attributable bmsgaap diluted eps attributable specified items diluted eps attributable bmsnongaap income taxes effective income tax rate earnings continuing operations income taxes effective income tax rate lower us statutory rate due decision indefinitely reinvest earnings certain manufacturing operations ireland puerto rico favorable tax rates ireland puerto rico grants scheduled expire prior fluctuations effective tax rate impacted million tax charge earnings mix high low tax jurisdictions contingent tax matters changes prior period estimates upon finalizing tax returns detailed discussion changes effective tax rate see item financial statements note income taxes future effective tax rate also adversely affected research development tax credit extended discontinued operations december completed splitoff remaining interest mead johnson means exchange offer bms shareholders see item financial statementsnote mead johnson nutrition company initial public offering splitoff noncontrolling interest noncontrolling interest primarily related partnerships sanofi territory covering americas related plavix net sales see item financial statementsnote alliances collaborations increase noncontrolling interest corresponds increased net sales plavix us following expected loss exclusivity plavix avaproavalide us expect significant decrease net earnings attributable noncontrolling interest net earnings discontinued operations attributable noncontrolling interest primarily relates publicly owned portion mead johnson prior complete divestiture splitoff summary noncontrolling interest follows year ended december dollars millions sanofi partnerships noncontrolling interestpretax income taxes net earnings continuing operations attributable noncontrolling interestnet taxes net earnings discontinued operations attributable noncontrolling interestnet taxes net earnings attributable noncontrolling interestnet taxes financial position liquidity capital resources net cash position follows dollars millions cash cash equivalents marketable securitiescurrent marketable securitiesnoncurrent total cash cash equivalents marketable securities shortterm borrowings including current portion longterm debt longterm debt net cash position maintain significant level working capital approximately billion december billion december future periods expect cash generated us operations together existing cash cash equivalents marketable securities borrowings capital markets sufficient cover cash needs dividends common stock repurchases debt repurchases strategic alliances acquisitions including acquisition inhibitex billion milestone payments working capital capital expenditures rely shortterm borrowings meet current liquidity needs cash cash equivalents marketable securities held us billion december approximately billion remaining billion held low tax jurisdictions attributable earnings expected indefinitely reinvested offshore cash repatriations subject restrictions certain jurisdictions may subject withholding taxes investment portfolio includes noncurrent marketable securities subject changes fair value result interest rate fluctuations market factors may impact results operations investment policy places limits investments amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards see item financial statementsnote financial instruments discussed strategy loss exclusivity us largest product plavix may expected result rapid precipitous material decline operating cash flow additional regulations us could passed future could reduce results operations operating cash flow liquidity financial flexibility also continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers ability collect outstanding receivables direct customers currently believe economic conditions eu material impact liquidity cash flow financial flexibility mechanism limit overall credit exposures additional source liquidity sell trade receivables third parties principally wholesalers japan certain governmentbacked entities italy portugal spain sales trade receivables totaled approximately billion million million amount trade receivables sold italy portugal spain million million million may available factored future due ongoing european sovereign debt crisis sales agreements allow recourse event uncollectibility retain interest underlying asset sold september company replaced billion revolving credit facility new billion five year revolving credit facility syndicate lenders contains customary terms conditions extendable anniversary date consent lenders financial covenants new facility borrowings outstanding either revolving credit facility december december continue manage operating cash flows initiatives designed improve working capital items directly affected changes sales volume receivables inventories accounts payable following summarizes components expressed percentage trailing twelve months net sales trailing trailing december twelve month december twelve month dollars millions net sales net sales net trade receivables inventories accounts payable total credit ratings moodys investors service moodys longterm shortterm credit ratings currently prime respectively longterm credit outlook remains stable standard poors sp longterm shortterm credit ratings currently respectively longterm credit outlook remains stable fitch ratings fitch longterm shortterm credit ratings currently f respectively longterm credit outlook remains negative credit ratings considered investment grade longterm ratings designate low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings designate strongest capacity timely repayment cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts cash disbursements activities investing activities financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees pension contributions tax payments ordinary course business operating cash flow continued benefit improved operating performance working capital initiatives higher unpaid rebates due part timing increasing lag payments managed care organizations attributed government agencies administrative delays investing activities net purchases marketable securities million billion billion investments time deposits highly rated corporate debt securities maturities greater days increased manage return investment cash used fund acquisitions amira million including million contingent payment zymogenetics million medarex billion capital expenditures million million million including costs related devens biologics facility costs support several manufacturing initiatives proceeds million received sale businesses within asiapacific region mead johnson cash included splitoff transaction million financing activities dividend payments billion billion billion dividends declared per common share december declared quarterly dividend per common share expect pay dividend full year per share dividend decisions made quarterly basis board directors billion stock repurchase program authorized may resulting repurchase common stock billion million management periodically evaluates potential opportunities repurchase certain debt securities terminate certain interest rate swap contracts prior maturity cash outflows related repurchase debt million million million proceeds termination interest rate swap contracts million million million proceeds issuances common stock resulting stock option exercises million including million cash retained excess tax benefits million million issuance common stock result stock option exercises vary period based upon fluctuations market value stock relative exercise price stock options factors proceeds billion received mead johnson initial public offering issuance mead johnson notes contractual obligations payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb longterm liabilities totalc includes estimated future interest payments shortterm longterm debt securities also includes accrued interest payable recognized consolidated balance sheets consists primarily accrued interest shortterm longterm debt well accrued periodic cash settlements derivatives b due uncertainty related timing reversal uncertain tax positions shortterm uncertain tax benefits provided table see item financial statementsnote income taxes detail c table excludes future contributions us pensions postretirement postemployment benefit plans required contributions contingent upon numerous factors including minimum regulatory funding requirements funded status plan due uncertainty future obligations excluded table contributions us international plans expected million see item financial statementsnote pension postretirement postemployment liabilities detail addition committed billion aggregate potential future research development milestone payments third parties part inlicensing development programs early stage milestones defined milestones achieved phase iii clinical trials comprised billion total committed amount late stage milestones defined milestones achieved post phase iii clinical trials comprised billion total committed amount payments agreements generally due payable upon achievement certain developmental regulatory milestones specific timing predicted addition certain royalty obligations calculated percentage net sales agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations see item financial statementsnote alliances collaborations information regarding alliances discussion contractual obligations see item financial statementsnote pension postretirement postemployment liabilities note financial instruments note leases sec consent order previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain inventory management agreements imas us pharmaceutical wholesalers account nearly total gross sales us biopharmaceuticals products current terms imas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately total gross sales us biopharmaceuticals products inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us biopharmaceuticals businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast biopharmaceuticals business outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards see item financial statementsnote accounting policies discussion impact related recently issued accounting standards critical accounting policies prepare financial statements conformity accounting principles generally accepted us preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period critical accounting policies important financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain new discounts us healthcare reform law medicare coverage gap managed medicaid require additional assumptions due lack historical claims experience increasing lag claims data addition new pharmaceutical company fee estimate subject external data including companys relative share industry results uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates accounting policies discussed audit committee board directors revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates recognize revenue persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment net grosstonet sales adjustments discussed involve significant estimates judgments grosstonet sales adjustments following categories grosstonet sales adjustments involve significant estimates judgments require us use information external sources see net sales discussion analysis significant category grosstonet sales adjustments chargebacks related government programs us businesses participate programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price account chargebacks reducing accounts receivable amount equal estimate chargeback claims attributable sale estimate chargebacks primarily based historical experience regarding programs chargebacks current contract prices programs consider chargeback payments levels inventory distribution channel claim processing time lag adjust reserve reflect actual experience cash discounts us certain countries offer cash discounts incentive prompt payment generally approximating sales price account estimated cash discounts reducing accounts receivable based historical claims experience adjust reserve reflect actual experience managed healthcare rebates contract discounts offer rebates discounts managed healthcare organizations us manage prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well globally contract counterparties hospitals group purchasing organizations beginning rebates medicare part program included discount companys brandname drugs patients fall within medicare part coverage gap addition accrue rebates us department defense tricare retail pharmacy refund program account rebates discounts establishing accrual primarily based historical experience current contract prices consider sales performance products subject rebates discounts increasing level unbilled claims levels inventory distribution channel adjust accrual reflect actual experience medicaid rebates us businesses participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities discounts rebates provided programs included medicaid rebate accrual considered medicaid rebates purposes discussion retroactive january minimum rebates medicaid drug sales increased medicaid rebates also extended drugs used managed medicaid plans beginning march account medicaid rebates establishing accrual primarily based historical experience well expansion prospective basis participation programs legal interpretations applicable laws new information regarding changes medicaid programs regulations guidelines would impact amount rebates consider outstanding medicaid claims increasing amount unbilled managed medicaid claims levels inventory distribution channel adjust accrual reflect actual experience sales returns account sales returns establishing accrual amount equal estimate sales recognized related products expected returned primarily result product expirations returns established products determine estimate sales return accrual primarily based historical experience regarding sales returns also consider factors could impact sales returns factors include levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products instances expected precipitous declines demand following loss exclusivity consider factors adjust accrual reflect actual experience sales returns accruals new products estimated primarily based historical sales returns experience similar products within line product within similar therapeutic category limited circumstances new product extension existing line product historical experience products similar therapeutic category reliably estimate expected returns new product defer recognition revenue right return longer exists developed sufficient historical experience estimate sales returns estimated levels inventory distribution channel projected demand also considered new products yervoy net sales million deferred patient infusion due returns policy established third quarter us pharmaceutical company fee pharma fee began paying annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare pharma fee amount finalized preliminary funding based information oneyear lag pharma fee calculated based market data company well industry participants company full visibility fee classified financial reporting purposes operating expense use information external sources use information external sources estimate grosstonet sales adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits pension postretirement benefit plans accounted using actuarial valuations include key assumptions discount rates expected longterm rates return plan assets consultation actuaries key assumptions others salary growth retirement turnover healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citigroup pension discount curve used us plans us plans pension expense determined using weightedaverage discount rate present value benefit obligations december us plans determined using discount rate discount rate used determining us plans pension expense reduced expense would increased approximately million assumed discount rate used determining projected benefit obligation december reduced projected benefit obligation would increased approximately billion expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million detailed discussion retirement benefits see item financial statementsnote pension postretirement postemployment liabilities business combinations assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill determining fair value intangible assets including iprd typically use income method method starts forecast expected future net cash flows risk adjusted based estimated probabilities technical regulatory success adjusted present value applying appropriate discount rate reflects risk associated cash flow streams assets valued market participant view following approaches utilized specific intangible assets acquired iprd values preexisting relationship acquiree consider terms respective collaboration arrangement including cost profit sharing splits projects unit account typically global view would consider potential jurisdictions indications technology related specific platforms valued based upon expected annual number antibodies achieving early candidate nomination status technology commercial products valued utilizing multiperiod excessearnings method income approach premise value intangible asset equal present value aftertax cash flows solely attributed intangible asset licenses valued utilizing discounted cash flow method based estimates future riskadjusted milestone royalty payments projected earned respective products estimated economic term significant estimates assumptions include estimates projected cash flows cash flow projections represent would realizable market participant purchaser iprd assume initial positive cash flows commence shortly receipt expected regulatory approvals typically may occur number years actual cash flows attributed project likely different assumed since projections subjected multiple factors including trial results regulatory matters could materially change respective iprds ultimate commercial success well significantly alter costs develop respective iprd commercially viable products probability regulatory success ptrs rate ptrs rates based upon industry averages considering respective iprds development stage sought disease indications adjusted specific information data known iprd time acquisition subsequent clinical results internal external data obtained could alter ptrs rate materially impact intangible value discount rate select discount rate measures risks inherent future cash flows assessment assets life cycle competitive trends impacting asset including consideration technical legal regulatory economic barriers entry well expected changes standards practice indications addressed asset useful life determining useful life intangible asset based upon period expected contribute future cash flows pertinent matters associated asset environment operates considered including legal regulatory contractual provisions well effects obsolescence demand competition economic factors see item financial statementsnote acquisitions specific details values assigned assets acquired liabilities assumed acquisitions amira september zymogenetics october medarex september significant estimates utilized time valuations support fair values lead compounds within acquisitions include phase year first discount development ptrs rate projected positive dollars millions fair value rate utilized acquisition date utilized cash flow amira phase ii zymogenetics pegylatedinterferon lambda phase iib medarex yervoy phase iii impairment goodwill goodwill tested least annually impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill considered impaired carrying amount reporting units goodwill exceeds estimated fair value geographical reporting units aggregated impairment testing purposes based upon recent annual impairment test completed first quarter fair value goodwill substantially excess related carrying value discussion goodwill acquired inprocess research development intangible assets see item financial statementsnote accounting policiesgoodwill acquired inprocess research development intangible assets indefinitelived intangible assets including iprd indefinitelived intangible assets subject amortization tested impairment annually frequently events changes circumstances indicate asset might impaired consider various factors including stage development current legal regulatory environment competitive landscape adverse trial results significant delays obtaining marketing approval inability bring respective product market could result related intangible assets partially fully impaired commercialized products inability meet sales forecasts could result related intangible assets partially fully impaired considering industrys success rate bringing developmental compounds market iprd impairment charges may occur future periods recognized charges million million related three medarex projects development ceased contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives judgments subject change adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion net valuation allowances billion december billion net valuation allowances billion december recognized deferred tax assets december related us federal net operating loss carryforward million us federal research development tax credit carryforward million net operating loss carryforward expires varying amounts beginning research development tax credit carryforwards expire varying amounts beginning realization carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured believe likely deferred tax assets realized provide taxes undistributed earnings foreign subsidiaries expected reinvested indefinitely offshore company completed internal reorganization certain legal entities contributed million tax charge recognized fourth quarter possible us tax authorities could assert additional material tax liabilities arising reorganization assertion occur company would vigorously challenge assertion believes would prevail however assurance result prior mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions relied upon certain assumptions representations covenants mead johnson regarding future conduct business matters could effect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement example mead johnson agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets agreed indemnify mead johnson certain taxes related business prior completion ipo created part restructuring facilitate ipo established liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk exposed market risk due changes currency exchange rates interest rates result certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk consider part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant portion revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen canadian dollar chinese renminbi australian dollar foreign currency forward contracts used manage foreign exchange risk primarily arises certain intercompany purchase transactions designate derivative instruments foreign currency cash flow hedges appropriate addition exposed foreign exchange transaction risk arises nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset portion exposures designated hedges changes fair value derivatives recognized earnings incurred estimate appreciation underlying currencies hedged levels us dollar december variables held constant would decrease fair value foreign exchange forward contracts held december million realized would negatively affect earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges recognized part foreign currency translation component accumulated oci net investment fall equivalent value euro debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information see item financial statementsnote financial instruments interest rate risk fixedtofloating interest rate swaps used designated fairvalue hedges part interest rate risk management strategy swaps intended provide us appropriate balance fixed floating rate debt estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swaps million excluding effects counterparty credit risk realized would affect earnings remaining life swaps marketable securities subject changes fair value result interest rate fluctuations market factors policy invest institutions meet high credit quality standards estimate increase basis points interest rates general would decrease fair value debt security portfolio approximately million credit risk exposure european sovereignbacked trade receivables material continue limit credit exposure certain countries significantly impacted sovereign debt crisis europe identified governmentbacked entities higher risk default monitoring social economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios although material provided additional bad debt reserves italy greece portugal spain also defer immaterial amount revenues certain governmentbacked entities greece portugal spain collections reasonably assured periodically sell certain nonus trade receivables means reduce collectability risk sales agreements provide recourse event uncollectibility retain interest underlying asset sold volume trade receivables sold italy portugal spain may sustainable future years due ongoing european sovereign debt crisis monitor investments counterparties objective minimizing concentrations credit risk investment policy places limits amount time maturity investments individual counterparty policy also requires investments made primarily highly rated corporate financial us government government supported institutions use derivative instruments exposes us credit risk fair value derivative instrument contract positive exposed credit risk counterparty fails perform fair value derivative instrument contract negative counterparty exposed credit risk fail perform obligation terms agreements posting collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information see item financial statements note financial instruments bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data item financial statements supplementary data year ended december earnings net sales cost products sold marketing selling administrative advertising product promotion research development provision restructuring litigation expense net equity net income affiliates incomeexpense total expenses earnings continuing operations income taxes provision income taxes net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings discontinued operations net earnings net earnings attributable noncontrolling interest net earnings attributable bristolmyers squibb company amounts attributable bristolmyers squibb company net earnings continuing operations net earnings discontinued operations net earnings attributable bristolmyers squibb company earnings per common share continuing operations attributable bristolmyers squibb company basic diluted earnings per common share attributable bristolmyers squibb company basic diluted dividends declared per common share accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss foreign currency translation foreign currency translation reclassified net earnings due business divestitures foreign currency translation net investment hedges derivatives qualifying cash flow hedges net taxes derivatives qualifying cash flow hedges reclassified net earnings net taxes derivatives reclassified net earnings due business divestitures net taxes pension postretirement benefits net taxes pension postretirement benefits reclassified net earnings net taxes pension postretirement benefits reclassified net earnings due business divestitures net taxes available sale securities net taxes available sale securities reclassified net earnings net taxes total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bristolmyers squibb company accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories deferred income taxes prepaid expenses total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses deferred income accrued rebates returns us foreign income taxes payable dividends payable total current liabilities pension postretirement postemployment liabilities deferred income us foreign income taxes payable liabilities longterm debt total liabilities commitments contingencies note equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities net earnings attributable noncontrolling interest depreciation amortization deferred income tax expense stockbased compensation expense impairment charges gain related divestitures discontinued operations adjustments changes operating assets liabilities receivables inventories accounts payable deferred income us foreign income taxes payable net cash provided operating activities cash flows investing activities proceeds sale maturities marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds sale businesses investing activities mead johnsons cash splitoff purchase businesses net cash acquired net cash used investing activities cash flows financing activities shortterm debt repayments longterm debt borrowings longterm debt repayments interest rate swap terminations issuances common stock common stock repurchases dividends paid proceeds mead johnson initial public offering net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements note accounting policies basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap include accounts bristolmyers squibb company may referred bristolmyers squibb bms company controlled majorityowned subsidiaries intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date codevelopment cocommercialization license arrangements entered parties various therapeutic areas terms including upfront licensing contingent payments arrangements assessed determine whether terms give economic control entity may require consolidation entity entities consolidated controlled means majority voting interest referred variable interest entities arrangements material variable interest entities including associated codevelopment cocommercialization license arrangements determined exist use estimates preparation financial statements requires use management estimates assumptions based complex judgments significant assumptions employed estimates used determining fair value intangible assets restructuring charges accruals sales rebate return accruals including related us healthcare reform legal contingencies tax assets tax liabilities stockbased compensation expense pension postretirement benefits including actuarial assumptions see note pension postretirement postemployment liabilities fair value financial instruments direct observable market quotes inventory obsolescence potential impairment longlived assets allowances bad debt well estimates used applying revenue recognition policy new discounts us healthcare reform law medicare coverage gap managed medicaid require additional assumptions due lack historical claims experience addition new pharmaceutical company fee estimate subject external data well calculation based companys relative share industry results actual results may differ estimated results revenue recognition revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment however certain sales made nonus businesses recognized date receipt purchaser see note alliances collaborations discussion revenue recognition related alliances provisions made time revenue recognition expected sales returns discounts rebates estimated sales allowances based historical experience updated changes facts circumstances including impact new legislation provisions recognized reduction revenue limited circumstances new product extension existing line product historical experience products similar therapeutic category exists revenue deferred right return longer exists sufficient historical experience estimate sales returns developed income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made cash cash equivalents cash cash equivalents consist us treasury securities government agency securities bank deposits time deposits money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable securities investments companies marketable securities classified availableforsale date purchase reported fair value december fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity declines fair value considered temporary charged earnings considered temporary reported component accumulated comprehensive income oci shareholders equity declines fair value determined credit related charged earnings average cost method used determining realized gains losses sale availableforsale securities investments less owned companies ability exercise significant influence maintained accounted using equity method accounting share net income losses equity investments included equity net income affiliates consolidated statements earnings equity investments reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment length time extent market value less cost financial condition investee inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets estimated useful lives depreciable assets range years buildings years machinery equipment fixtures impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows longlived assets held sale reported lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software costs obtain software projects significant expensed incurred business combinations businesses acquired included consolidated financial statements upon obtaining control acquiree assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill legal costs audit fees business valuation costs business acquisition costs expensed incurred goodwill acquired inprocess research development intangible assets goodwill tested impairment annually using twostep process first step identifies potential impairment second step measures amount impairment loss goodwill impaired carrying amount reporting units goodwill exceeds estimated fair value geographical reporting units aggregated impairment testing purposes annual goodwill impairment assessment completed first quarter subsequently monitored potential impairment remaining quarters none indicated impairment goodwill fair value inprocess research development iprd acquired business combination determined based present value research projects projected cash flows using income approach future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted probability regulatory success resulting cash flows discounted rate approximating companys weightedaverage cost capital iprd initially capitalized considered indefinitelived assets subject annual impairment reviews often upon occurrence certain events review requires determination fair value respective intangible assets fair value intangible assets less carrying value impairment loss recognized difference compounds reach commercialization assets amortized expected useful lives patentstrademarks licenses technology amortized straightline basis estimated useful lives monitored impairment triggers considered impaired net carrying value exceeds estimated fair value restructuring restructuring charges recognized result actions streamline operations rationalize manufacturing facilities judgment used estimating impact restructuring plans including future termination benefits exit costs incurred actions take place actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur wide range matters including government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies recognized realized legal fees expensed incurred derivative financial instruments derivative financial instruments used principally management interest rate foreign currency exposures held issued trading purposes derivative instruments recognized fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated cash flow hedge effective portions changes fair value derivative reported accumulated comprehensive income oci subsequently recognized earnings hedged item affects earnings cash flows classified consistent underlying hedged item derivatives designated assigned hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer probable occur gain loss immediately recognized designated hedge earnings nonderivative instruments also designated hedges net investments foreign affiliates nonderivative instruments mainly euro denominated longterm debt effective portion designated nonderivative instrument recognized foreign currency translation section oci ineffective portion recognized earnings shipping handling costs shipping handling costs included marketing selling administrative expenses million million million million included discontinued operations advertising product promotion costs advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized earnings research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred strategic alliances third parties provide rights develop manufacture market andor sell pharmaceutical products rights owned party certain research development payments alliance partners contingent upon achievement certain predetermined criteria milestone payments achieved prior regulatory approval product expensed research development milestone payments made connection regulatory approvals capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable research development recognized net reimbursements connection collaboration agreements upfront licensing milestone receipts obtained development deferred amortized estimated life product income company future obligation development upfront licensing milestone receipts recognized immediately income amortization period upfront licensing milestone receipts new materially modified arrangement january assessed determined considering terms arrangements recently issued accounting standards january new revenue recognition standard adopted new materially modified revenue arrangements upfront licensing fees contingent milestones relating research development deliverables guidance provides principles application guidance whether multiple deliverables exist arrangement separated consideration allocated adoption standard impact consolidated financial statements september fasb amended guidance goodwill impairment testing amendment allows entities first assess qualitative factors determining whether fair value reporting unit exceeds carrying value entity concludes qualitative assessment likely fair value reporting unit exceeds carrying value performing twostep impairment test unnecessary standard effective fiscal years beginning december expected impact consolidated financial statements note business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization global supply chain organization utilized responsible development delivery products market products distributed sold regional organizations serve united states europe latin america middle east africa japan asia pacific canada emerging markets defined brazil russia india china turkey business also supported global corporate staff functions segment information presented consistent financial information regularly reviewed chief operating decision maker chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross sales three largest pharmaceutical wholesalers us percentage total gross sales follows mckesson corporation cardinal health inc amerisourcebergen corporation selected geographic area information follows property plant net sales equipment dollars millions united states europe japan asia pacific canada latin america middle east africa emerging markets total net sales key products follows year ended december dollars millions plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide abilify aripiprazole reyataz atazanavir sulfate sustiva efavirenz franchise baraclude entecavir erbitux cetuximab sprycel dasatinib yervoy ipilimumab orencia abatacept nulojix belatacept onglyzakombiglyze saxagliptinsaxagliptin metformin mature products net sales capital expenditures depreciation property plant equipment within segment follows year ended december dollars millions capital expenditures depreciation segment income excludes impact significant items indicative current operating performance ongoing results earnings attributed sanofi noncontrolling interest reconciliation earnings continuing operations income taxes follows year ended december dollars millions segment income reconciling items provision restructuring impairment loss sale manufacturing operations accelerated depreciation asset impairment shutdown costs process standardization implementation costs gain sale product lines businesses assets litigation recoverycharges upfront milestone licensing payments bms foundation funding initiative noncontrolling interest earnings continuing operations income taxes note alliances collaborations sanofi bms agreements sanofi codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire upon expiration patents exclusivity rights applicable territory bms acts operating partner owns majority controlling interest territory covering americas australia consolidates country partnership results territory sanofis share results reflected noncontrolling interest bms recognizes net sales territory comarketing countries outside territory eg germany italy irbesartan spain greece royalties owed sanofi included cost products sold development royalties sanofi acts operating partner owns majority controlling interest territory covering europe asia bms ownership interest territory accounts equity method distributions profits relating partnerships included operating activities bms sanofi separate partnership governing copromotion irbesartan us bms recognizes income related amortization deferred income associated sanofis million payment bms acquisition interest irbesartan license us upon formation alliance certain supply activities development optout royalties sanofi reflected net basis incomeexpense fourth quarter bms established million reserve related avalide supply disruption early connection ongoing negotiations sanofi charge included expense summarized financial information related alliance follows year ended december dollars millions territory covering americas australia net sales royalty expense noncontrolling interest pretax profit distributions sanofi territory covering europe asia equity net income affiliates profit distributions bms net sales europe comarketing countries amortization incomeexpense irbesartan license fee supply activities development optout royalty incomeexpense december dollars millions investment affiliates territory covering europe asia deferred income irbesartan license fee following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales cost products sold gross profit marketing selling administrative advertising product promotion research development incomeexpense net income current assets current liabilities cost products sold includes discovery royalties million million million paid directly sanofi expenses shared based applicable ownership percentages current assets current liabilities include approximately million million billion related receivablespayables attributed respective years net cash distributions bms sanofi well intercompany balances partnerships within territory remaining current assets current liabilities consist thirdparty trade receivables inventories amounts due bms sanofi purchase inventories royalties expense reimbursements otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify treatment schizophrenia bipolar mania disorder major depressive disorder excluding certain asia pacific countries us portion amended commercialization manufacturing agreement expires upon expected loss product exclusivity april contractual share abilify net sales recognized bms beginning january contractual share revenue recognized bms reduced uk germany france spain bms receives thirdparty net sales countries us thirdparty customers invoiced bms behalf otsuka alliance revenue recognized abilify shipped risks rewards ownership transferred third party customers certain countries bms presently exclusive distributor product exclusive right sell abilify bms recognizes net sales bms purchases product otsuka performs finish manufacturing sale thirdparty customers bms otsuka terms amended agreement bms paid otsuka million amortized reduction net sales expected loss us exclusivity april unamortized balance included assets otsuka receives royalty based total us net sales included cost products sold otsuka responsible us expenses related commercialization abilify reimbursements netted principally marketing selling administrative advertising product promotion expenses beginning january expected loss us exclusivity april including expected six month pediatric extension bms receive following percentages us annual net sales share us net sales billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible us expenses related commercialization abilify bms otsuka also entered oncology collaboration sprycel ixempra us japan european union eu markets oncology territory collaboration fee classified cost products sold paid otsuka based following percentages annual net sales sprycel ixempra oncology territory net sales million million million million million million billion excess billion periods otsuka contributes first million certain commercial operational expenses relating oncology products ii commercial operational expenses relating products territory excess million beginning otsuka copromotes sprycel us japan exercised right copromote top five eu markets beginning january us extension oncology collaboration include changeofcontrol provision case acquisition bms acquiring company competing product abilify new company assume abilify agreement amended oncology collaboration exists today acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights bms abilify agreement amended agreements also provide event generic competitor abilify january bms option terminating abilify april amendment agreement previously amended remaining force bms exercise option either bms would receive payment otsuka according predetermined schedule oncology collaboration would terminate time ii oncology collaboration would continue truncated period according predetermined schedule eu agreement remained unchanged expire june countries bms exclusive right sell abilify agreement expires later th anniversary first commercial sale country expiration applicable patent country addition million extension payment total milestone payments made otsuka agreement december million million expensed iprd remaining million capitalized intangible assets amortized cost products sold remaining life original agreement us summarized financial information related alliance follows year ended december dollars millions abilify net sales including amortization extension payment oncology products collaboration fee expense royalty expense reimbursement operating expenses tofrom otsuka amortization incomeexpense extension payment amortization incomeexpense upfront milestone licensing payments december dollars millions assets extension payment intangible assets upfront milestone licensing payments january bms granted otsuka exclusive rights develop commercialize onglyza japan bms expects receive milestone payments based certain regulatory events well salesbased payments following regulatory approval onglyza japan retained rights copromote onglyza otsuka japan otsuka responsible development costs japan lilly bms epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lillys acquisition imclone systems incorporated imclone codevelopment promotion erbitux necitumumab imcf us expires erbitux september bms also codevelopment copromotion rights products canada japan erbitux indicated use treatment patients metastatic colorectal cancer use treatment squamous cell carcinoma head neck egfr agreement respect erbitux sales north america lilly receives distribution fee based flat rate net sales north america plus reimbursement certain royalties paid lilly included cost products sold bms imclone amended codevelopment agreement merck kgaa merck provide cocommercialization erbitux japan rights agreement expire however lilly ability terminate agreement determines commercially unreasonable lilly continue erbitux received marketing approval japan use erbitux treating patients advanced recurrent colorectal cancer bms receives pretax profit merck sales erbitux japan shared equally lilly profit sharing commercialization japan attributed bms included income bms amortizing million license acquisition costs bms lilly restructured egfr commercialization agreement described bms imclone relates necitumumab novel targeted cancer therapy currently phase iii development nonsmall cell lung cancer restructured companies share cost developing potentially commercializing necitumumab us canada japan lilly maintains exclusive rights necitumumab markets bms fund development costs studies used us japan studies fund global studies bms pay million lilly milestone payment upon first approval us us canada bms recognize sales profits losses necitumumab lilly provide selling effort parties general equally participate commercialization efforts japan bms lilly share commercial costs profits evenly agreement relates necitumumab continues beyond patent expiration parties agree terminate may terminated time bms months advance notice months prior launch either party uncured material breach parties agree terminate lilly responsible manufacturing bulk requirements bms responsible fillfinish necitumumab summarized financial information related alliance follows year ended december dollars millions net sales distribution fees royalty expense research development expense reimbursement lilly necitumumab amortization incomeexpense upfront milestone licensing payments japan commercialization fee incomeexpense december dollars millions intangible assets upfront milestone licensing payments gilead bms gilead sciences inc gilead joint venture develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen treatment human immunodeficiency virus hiv infection combining sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead us canada europe bms accounts participation us joint venture equity method accounting net sales bulk efavirenz component atripla deferred combined product sold thirdparty customers net sales efavirenz component based relative ratio average respective net selling prices truvada sustiva summarized financial information related alliance follows year ended december dollars millions net sales equity net loss affiliates astrazeneca bms maintains two worldwide codevelopment cocommercialization agreements astrazeneca plc astrazeneca onglyzakombiglyze excluding japan dapagliflozin onglyza kombiglyze indicated use treatment diabetes dapagliflozin currently studied treatment diabetes onglyza dapagliflozin discovered bms kombiglyze codeveloped astrazeneca companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis also share development costs bms manufactures products bms option decline involvement cocommercialization given country instead receive tiered royalty based net sales reimbursements development commercial cost sharing included research development advertising product promotion marketing selling administrative expenses expense attributable astrazenecas share profits included costs products sold bms received million upfront milestone licensing payments related saxagliptin december could receive additional million salesbased milestones bms also received million upfront milestone licensing payments related dapagliflozin december could potentially receive additional million development regulatory milestones additional million salesbased milestones upfront milestone licensing payments deferred amortized estimated useful life products income summarized financial information related alliance follows year ended december dollars millions net sales profit sharing expense commercialization expense reimbursements tofrom astrazeneca research development expense reimbursements tofrom astrazeneca amortization incomeexpense upfront milestone licensing payments upfront milestone licensing payments received saxagliptin dapagliflozin december dollars millions deferred income upfront milestone licensing payments saxagliptin dapagliflozin pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered bms prevention treatment atrial fibrillation arterial thrombotic conditions pfizer funds development costs initial development plan effective january companies jointly develop clinical marketing strategy share commercialization expenses profits equally global basis bms manufactures product reimbursements development costs commercial cost sharing included research development advertising product promotion marketing selling administrative expenses bms received million upfront milestone licensing payments eliquis date including million received january could receive additional million development regulatory milestones payments deferred amortized estimated useful life products income summarized financial information related alliance follows year ended december dollars millions commercialization expense reimbursements tofrom pfizer research development reimbursements tofrom pfizer amortization incomeexpense upfront milestone licensing payments upfront milestone licensing payments received december dollars millions deferred income upfront milestone licensing payments note acquisitions amira pharmaceuticals inc september bms acquired outstanding shares amira pharmaceuticals inc amira million cash plus three separate contingent million payments due upon achievement certain development salesbased milestones first contingent payment made fourth quarter fair value total contingent consideration million recorded liabilities acquisition costs million included expense amira privatelyheld biotechnology company primarily focused discovery development therapeutic products treatment cardiovascular fibrotic inflammatory diseases acquisition provides bms full rights develop commercialize completed phase clinical studies remainder amira lysophosphatidic acid receptor antagonist program researchers fibrotic expertise preclinical autotaxin program goodwill generated acquisition primarily attributed acquired scientific expertise fibrotic diseases allowing expansion new therapeutic class contingent liability estimated utilizing model assessed probability achieving milestone discounted amount potential payment based expected timing estimates used evaluating contingent liability consistent used evaluating acquired iprd discount rate payment consistent market debt yields noncallable publiclytraded bonds bms similar maturities estimated potential payment dates fair value measurement based significant inputs observable market therefore represents level measurement results amiras operations included consolidated financial statements september zymogenetics inc acquisition october bms acquired outstanding shares common stock zymogenetics inc zymogenetics october aggregate purchase price approximately million acquisition costs million included expense zymogenetics focused developing commercializing therapeutic proteinbased products treatment human diseases companies collaborated development pegylatedinterferon lambda novel interferon phase iib development acquisition date treatment hepatitis c infection acquisition provides company full rights develop commercialize pegylatedinterferon lambda valued million iprd acquisition date also brings proven capabilities therapeutic proteins revenue recothrom fda approved specialty surgical biologic goodwill generated acquisition primarily attributed full ownership rights pegylatedinterferon lambda results zymogenetics operations included consolidated financial statements october medarex inc acquisition september bms acquired means tender offer secondstep merger remaining outstanding shares stock equivalents medarex already owned total purchase price million acquisition costs million included expense medarex focused discovery development commercialization fully human antibodybased therapeutic products address major unmet healthcare needs areas oncology inflammation autoimmune disorders infectious diseases result acquisition full rights yervoy ipilimumab valued billion acquisition date received increases biologics development pipeline creating balanced portfolio small molecules biologics goodwill generated acquisition primarily attributed balanced portfolio associated biopharma model potential optimize existing yervoy programs results medarex operations included consolidated financial statements august purchase price allocations follows dollars millions amira zymogenetics medarex purchase price cash fair value contingent consideration fair value companys equity held prior acquisition total identifiable net assets cash marketable securities inventory current longterm assets iprd intangible assets technology intangible assets licenses shortterm borrowings accrued expenses current longterm liabilities deferred income taxes total identifiable net assets goodwill income million recognized remeasurement fair value equity interest medarex held acquisition date inventory related zymogenetics acquisition includes million recorded long term assets inventory expected utilized excess one year current long term assets related medarex acquisition includes ownership interest genmab inc million ownership celldex therapeutics inc million subsequently sold loss million pro forma supplemental financial information provided impacts acquisitions material operating results year acquisition goodwill iprd intangible assets valued acquisitions nondeductible tax purposes note mead johnson nutrition company initial public offering splitoff mead johnson nutrition company initial public offering february mead johnson nutrition company mead johnson completed initial public offering ipo sold million shares class common stock per share net proceeds million deducting million underwriting discounts commissions offering expenses allocated noncontrolling interest capital excess par value stock upon completion ipo million shares mead johnson class common stock million shares mead johnson class b common stock held bms representing interest mead johnson combined voting power outstanding common stock rights holders shares class common stock class b common stock identical except regard voting conversion share class common stock entitled one vote per share share class b common stock entitled ten votes per share convertible time election holder one share class common stock class b common stock automatically converted shares class common stock various agreements related separation mead johnson entered including separation agreement transitional services agreement tax matters agreement registration rights agreement employee matters agreement mead johnson nutrition company splitoff splitoff remaining interest mead johnson completed december splitoff effected exchange offer previously held million shares mead johnson converting class b common stock class common stock million outstanding shares companys stock resulting pretax gain million million net taxes shares received connection exchange valued using closing price december reflected treasury stock gain exchange determined using sum fair value shares received plus net deficit mead johnson attributable bms less taxes direct expenses related transaction including tax reserve million established transitional relationships discontinued operations subsequent respective dispositions cash flows income associated mead johnson business continue generated september relating activities transitional nature result agreements intended facilitate orderly transfer business operations include among others services accounting customer service distribution manufacturing income generated transitional activities substantially complete december material period presented following summarized financial information related mead johnson business segregated continuing operations reported discontinued operations date disposition year ended december dollars millions net sales earnings income taxes provision income taxes earnings net taxes gain disposal provision income taxes gain disposal net taxes net earnings discontinued operations less net earnings discontinued operations attributable noncontrolling interest net earnings discontinued operations attributable bms note restructuring following provision restructuring year ended december dollars millions employee termination benefits exit costs provision restructuring restructuring charges included termination benefits workforce reductions manufacturing selling administrative research development personnel across geographic regions approximately following table represents activity employee termination exit cost liabilities year ended december dollars millions liability beginning year charges change estimates provision restructuring foreign currency translation charges discontinued operations spending mead johnson splitoff liability end year note incomeexpense incomeexpense includes year ended december dollars millions interest expense interest income impairment loss sale manufacturing operations gain sale product lines businesses assets income received alliance partners pension curtailment settlement charges litigation chargesrecoveries product liability chargesrecoveries incomeexpense note income taxes provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision effective tax rate reconciliation effective tax rate us statutory federal income tax rate earnings income taxes dollars millions earnings continuing operations income taxes us nonus total us statutory rate nontax deductible annual pharmaceutical company fee tax effect foreign subsidiaries earnings previously considered indefinitely reinvested offshore foreign tax effect certain operations ireland puerto rico switzerland state local taxes net valuation allowance us federal state foreign contingent tax matters us federal research development tax credit foreign decrease effective tax rate due million charge recognized fourth quarter resulted primarily additional us taxable income earnings foreign subsidiaries previously considered indefinitely reinvested offshore changes prior period estimates upon finalizing us tax returns resulting million benefit million charge higher tax benefits contingent tax matters primarily related effective settlements remeasurements uncertain tax positions million million partially offset unfavorable earnings mix high low tax jurisdictions compared prior year nontax deductible annual pharmaceutical company fee effective january tax impact million outofperiod tax adjustment million previously unrecognized net deferred tax assets primarily attributed deferred profits related certain alliances december material prior periods increase effective tax rate due million charge recognized fourth quarter discussed changes prior period estimates upon finalizing us tax return resulting million charge million benefit upon finalizing us tax return unfavorable earnings mix high low tax jurisdictions compared prior year partially offset higher tax benefits contingent tax matters primarily related effective settlements remeasurements uncertain tax positions million million outofperiod tax adjustment million discussed deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards milestone payments license fees deferred income us federal net operating loss carryforwards pension postretirement benefits state net operating loss credit carryforwards intercompany profit inventory items us federal research development tax credit carryforwards foreign deferred tax assets sharebased compensation legal settlements total deferred tax assets valuation allowance net deferred tax assets deferred tax liabilities depreciation repatriation foreign earnings acquired intangible assets total deferred tax liabilities deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable current liabilities noncurrent total us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning research development tax credit carryforwards expire varying amounts beginning realization research development tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized december valuation allowance million established following items million foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards foreign holding companies net operating losses corresponding valuation allowances included increase million result statutory impairment charges required consolidated net earnings foreign holding companies higher asset basis statutory purposes basis used consolidated financial statements due internal reorganization certain legal entities prior periods changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation balance end year income tax payments million million million current tax benefit realized result stock related compensation credited capital excess par value stock million million million december us taxes provided approximately billion undistributed earnings foreign subsidiaries undistributed earnings indefinitely invested offshore future earnings repatriated us earnings determined remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided bms favorable tax rates ireland puerto rico grants scheduled expire prior bms completed internal reorganization certain legal entities resulting million charge possible us tax authorities could assert additional material tax liabilities arising reorganization assertion occur bms would vigorously challenge assertion believes would prevail however assurance result business conducted various countries throughout world subject tax numerous jurisdictions result significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported may require several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross reductions tax positions related current year gross additions tax positions related prior years gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year uncertain tax benefits reduce deferred tax assets extent uncertainty directly related asset otherwise recognized either current non current us foreign income taxes payable unrecognized tax benefits recognized would impact effective tax rate million million million december respectively gross additions tax positions year ended december include million tax reserves related transfer various international units mead johnson prior ipo splitoff transaction recognized discontinued operations gross reductions tax positions year ended december include million liabilities related mead johnson accrued interest penalties payable unrecognized tax benefits included either current noncurrent us foreign income taxes payable accrued interest related unrecognized tax benefits million million million december respectively accrued penalties related unrecognized tax benefits million million million december respectively interest penalties related unrecognized tax benefits included income tax expense interest unrecognized tax benefits expense million million benefit million penalties unrecognized tax benefits expense million million benefit million bms currently examination number tax authorities including major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses bms estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits primarily settlement related involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits bms also anticipates reasonably possible new issues raised tax authorities may require increases balance unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data basic eps calculation income continuing operations attributable bms earnings attributable unvested restricted shares income continuing operations attributable bms common shareholders net earnings discontinued operations attributable bms eps numerator basic eps denominator basic average common shares outstanding eps basic continuing operations discontinued operations net earnings eps numerator diluted income continuing operations attributable bms earnings attributable unvested restricted shares income continuing operations attributable bms common shareholders net earnings discontinued operations attributable bms eps numerator diluted eps denominator diluted average common shares outstanding contingently convertible debt common stock equivalents incremental shares attributable sharebased compensation plans average common shares outstanding common share equivalents eps diluted continuing operations discontinued operations net earnings net earnings discontinued operations used eps calculation net earnings discontinued operations attributable bms earnings attributable unvested restricted shares net earnings discontinued operations attributable bms used eps calculation antidilutive weightedaverage equivalent shares stock incentive plans note financial instruments financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives due short term maturity carrying amount receivables accounts payable approximate fair value bms exposure market risk due changes currency exchange rates interest rates result certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes counterparty credit risk considered part overall fair value measurement well effect credit risk derivatives liability position counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement terms agreements posting collateral required party whether derivatives asset liability position fair value measurements fair values financial instruments classified one following categories level inputs utilize nonbinding quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs instruments include us treasury bills us government agency securities level inputs utilize observable prices similar instruments nonbinding quoted prices identical similar instruments markets active observable inputs corroborated market data substantially full term assets liabilities instruments include corporate debt securities commercial paper federal deposit insurance corporation fdic insured debt securities certificates deposit money market funds foreign currency forward contracts interest rate swap contracts level derivative instruments valued using london interbank offered rate libor euro interbank offered rate euribor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably periodtoperiod due volatility underlying foreign currencies underlying interest rates driven market conditions duration contract credit adjustment volatility may significant impact valuation interest rate swaps due changes credit ratings credit default swap spreads bms counterparties level unobservable inputs used little market data available valuation models ars frs portfolio based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity majority ars private placement securities longterm nominal maturities rated standard poors december primarily represent interests insurance securitizations fair value determined using internally developed valuations based part indicative bids received underlying assets securities evidence fair value due current lack active market frs general lack transparency underlying assets qualitative analysis relied upon value frs including discussions brokers fund managers default risk underlying security overall capital markets liquidity availableforsale securities cash equivalents following table summarizes availableforsale securities december unrealized unrealized gain loss amortized accumulated accumulated fair fair value dollars millions cost oci oci value level level level december marketable securities certificates deposit corporate debt securities commercial paper us treasury bills fdic insured debt securities auction rate securities ars floating rate securities frs total marketable securities december marketable securities certificates deposit corporate debt securities commercial paper fdic insured debt securities us treasury bills us government agency securities auction rate securities ars floating rate securities frs total marketable securities following table summarizes classification availableforsale securities consolidated balance sheet december dollars millions current marketable securities noncurrent marketable securities total marketable securities money market funds securities aggregating million million december respectively included cash cash equivalents valued using level inputs cash cash equivalents maintained foreign currencies million december subject currency rate risk december million noncurrent available sale corporate debt securities us treasury bills fdic insured debt securities floating rate securities mature within five years auction rate securities mature beyond years following table summarizes activity financial assets utilizing level fair value measurements fair value january settlements unrealized gainslosses fair value december qualifying hedges nonqualifying derivatives following summarizes fair value outstanding derivatives december december fair value fair value dollars millions balance sheet location notional level notional level derivatives designated hedging instruments interest rate swap contracts assets foreign currency forward contracts assets foreign currency forward contracts accrued expenses cash flow hedges foreign currency forward contracts primarily utilized hedge forecasted intercompany inventory purchase transactions certain foreign currencies forward contracts designated cash flow hedges effective portion changes fair value temporarily reported accumulated oci recognized earnings hedged item affects earnings december significant outstanding foreign currency forward contracts primarily attributed euro japanese yen foreign currency forward contracts notional amount million million respectively net gains foreign currency forward contracts qualifying cash flow hedge accounting expected reclassified cost products sold within next two years including million pretax gains reclassified within next months cash flow hedge accounting discontinued forecasted transaction longer probable occurring originally forecasted date days thereafter hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis ineffective portion change fair value included current period earnings earnings impact related discontinued cash flow hedges hedge ineffectiveness significant net investment hedges nonus dollar borrowings million million designated hedge foreign currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gains losses remeasurement debt recognized foreign currency translation component accumulated oci related offset long term debt fair value hedges fixedtofloating interest rate swap contracts designated fair value hedges used part interest rate risk management strategy create appropriate balance fixed floating rate debt swaps underlying debt benchmark risk hedged recorded fair value effective interest rate paid fixedtofloating interest rate swaps onemonth libor december plus interest rate spread ranging underlying swap terminated prior maturity fair value basis adjustment underlying debt instrument amortized earnings reduction interest expense remaining life debt fixedtofloating interest rate swap contracts executed convert million notional amount debentures due million notional amount debentures due fixed rate debt variable rate debt fixedtofloating interest rate swap contracts executed convert million notional amount notes due notional amount notes due fixed rate debt variable rate debt contracts qualified fair value hedge debt instrument fixedtofloating interest rate swap contracts billion notional amount billion notional amount terminated generating total proceeds million including accrued interest million fixedtofloating interest rate swap contracts million notional amount million notional amount terminated generating total proceeds million including accrued interest million million notional amount fixedtofloating interest rate swap contracts terminated generating proceeds million including accrued interest million nonqualifying foreign exchange contracts foreign currency forward contracts used offset exposure foreign currencydenominated monetary assets liabilities earnings primary objective contracts protect us dollar value foreign currencydenominated monetary assets liabilities earnings effects volatility foreign exchange rates might occur prior receipt settlement us dollars contracts designated hedges adjusted fair value incomeexpense occur substantially offset change fair value underlying foreign currency denominated monetary asset liability earnings effect nonqualifying hedges earnings significant years ended december shortterm borrowings longterm debt shortterm borrowings include december dollars millions bank drafts shortterm borrowings total longterm debt includes december dollars millions principal value notes due euro notes due euro notes due notes due notes due notes due debentures due debentures due debentures due othermaturing subtotal adjustments principal value fair value interest rate swaps unamortized basis adjustment swap terminations unamortized bond discounts total included debt million floating rate convertible senior debentures due redeemed holders par september fundamental change ownership occurs debentures callable par time company debentures current conversion price equal conversion rate shares principal amount subject certain antidilutive adjustments february mead johnson entered threeyear syndicated revolving credit facility agreement fourth quarter mead johnson borrowed million revolving credit facility issued various notes totaling billion proceeds used repay certain intercompany debt prior splitoff principal value longterm debt obligations million december million due million due remaining million due thereafter fair value longterm debt million million december respectively estimated based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments debt repurchase activity follows dollars millions principal amount repurchase price notional amount interest rate swaps terminated swap termination proceeds total gainloss interest payments million million net amounts related interest rate swap contracts september company replaced billion revolving credit facility new billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders financial covenants new facility borrowings outstanding either revolving credit facility december december million financial guarantees provided form standby letters credit performance bonds standby letters credit issued financial institutions support guarantees made bms affiliates various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded note receivables receivables include december dollars millions trade receivables less allowances net trade receivables alliance partners receivables prepaid refundable income taxes miscellaneous receivables receivables receivables netted deferred income related alliance partners recognition income result alliance partner receivables deferred income reduced million million december respectively additional information regarding alliance partners see note alliances collaborations nonus receivables sold nonrecourse basis million million million aggregate receivables due three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization discontinued operations balance end year note inventories inventories include december dollars millions finished goods work process raw packaging materials inventories inventories expected remain onhand beyond one year included noncurrent assets million including million capitalized costs subject regulatory approval prior sold december million december status regulatory approval process probability future sales considered assessing recoverability costs note property plant equipment property plant equipment includes december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment depreciation expense million million million million included discontinued operations capitalized interest million million note goodwill intangible assets changes carrying amount goodwill follows dollars millions balance january zymogenetics acquisition balance december amira acquisition balance december includes outofperiod adjustment recorded correct purchase price allocation september medarex acquisition million contingent milestone payment prior acquisition medarex purchase price adjustment decreased intangible assets million increased deferred tax assets million goodwill million effect adjustment material current prior periods intangible assets include december december gross net gross net estimated carrying accumulated carrying carrying accumulated carrying dollars millions useful lives amount amortization amount amount amortization amount licenses years technology years capitalized software years total finitelived intangible assets iprd total intangible assets billion iprd reclassified technology upon approval yervoy us million iprd reclassified licenses licensed compounds performance obligations changes intangible assets follows dollars millions intangible assets carrying amount january capitalized software additions acquisitions mead johnson splitoff amortization licenses technology amortization capitalized software impairment charges intangible assets carrying amount december amortization expense included discontinued operations million amortization expense intangible assets expected million million million million million million thereafter note accrued expenses accrued expenses include december dollars millions employee compensation benefits royalties accrued research development restructuringcurrent pension postretirement benefits accrued litigation total accrued expenses note sales rebates return accruals reductions trade receivables accrued rebates returns liabilities follows december dollars millions chargebacks related government programs cash discounts reductions trade receivables managed healthcare rebates contract discounts medicaid rebates sales returns adjustments accrued rebates returns note deferred income deferred income includes december dollars millions upfront milestone licensing receipts atripla deferred revenue gain saleleaseback transactions total deferred income current portion noncurrent portion upfront milestone licensing receipts amortized expected life product see note alliances collaborations information pertaining revenue recognition transactions alliances collaborations deferred gains several saleleaseback transactions amortized remaining lease terms related facilities million million million note equity capital common stock excess treasury stock par value retained noncontrolling dollars shares millions shares par value stock earnings shares cost interest balance january net earnings attributable bms cash dividends declared mead johnson ipo adjustments mead johnson net asset transfer mead johnson splitoff employee stock compensation plans net earnings attributable noncontrolling interest comprehensive income attributable noncontrolling interest distributions balance december net earnings attributable bms cash dividends declared stock repurchase program employee stock compensation plans net earnings attributable noncontrolling interest distributions balance december net earnings attributable bms cash dividends declared stock repurchase program employee stock compensation plans net earnings attributable noncontrolling interest comprehensive income attributable noncontrolling interest distributions balance december treasury stock recognized cost reacquire shares treasury shares acquired mead johnson splitoff recognized fair value stock splitoff date shares issued treasury recognized utilizing firstin firstout method may board directors authorized repurchase billion common stock repurchases may made either open market private transactions including repurchase plans established accordance rule b securities exchange act amended stock repurchase program expiration date may suspended discontinued time noncontrolling interest primarily related partnerships sanofi territory covering americas net sales plavix net earnings attributable noncontrolling interest presented net taxes million million million consolidated statements earnings corresponding increase provision income taxes distribution partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis activity includes pretax income distributions related partnerships net earnings noncontrolling interest included discontinued operations million accumulated balances related component comprehensive incomeloss oci net taxes follows derivatives pension accumulated foreign qualifying currency effective postretirement available comprehensive dollars millions translation hedges benefits sale securities incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss balance december note pension postretirement postemployment liabilities company certain subsidiaries sponsor defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covers us employees represents approximately consolidated pension plan assets obligations funding policy contribute least minimum amount required employee retirement income security act erisa plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixedincome securities comprehensive medical group life benefits provided substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us net periodic benefit cost defined benefit pension postretirement benefit plans includes pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service costbenefit amortization net actuarial loss curtailments settlements special termination benefits total net periodic benefit cost continuing operations discontinued operations total net periodic benefit cost net actuarial loss prior service cost million expected amortized accumulated oci net periodic benefit cost pension postretirement benefit plans us retirement income plan several plans amended june amendments eliminate crediting future benefits relating service effective december salary increases continue considered additional fiveyear period determining benefit obligation related prior service plan amendments accounted curtailment result applicable plan assets obligations remeasured remeasurement resulted million reduction accumulated oci million net taxes corresponding decrease funded status plan due curtailment updated plan asset valuations change discount rate curtailment charge million also recognized expense second quarter remaining amount unrecognized prior service cost addition participants reclassified inactive benefit plan purposes actuarial gains losses amortized expected weightedaverage remaining lives plan participants years connection plan amendment contributions principal defined contribution plans us puerto rico increased effective january net impact actions expected reduce future retiree benefit costs although future costs continue subject market conditions factors including actual expected plan asset performance interest rate fluctuations lumpsum benefit payments certain plan assets related obligations transferred us retirement income plan several plans new plans sponsored mead johnson active mead johnson participants resulting million reduction accumulated oci million net taxes first quarter corresponding decrease funded status plan due updated plan asset valuations change discount rate changes defined benefit postretirement benefit plan obligations assets funded status amounts recognized consolidated balance sheets follows pension benefits benefits dollars millions benefit obligations beginning year service costbenefits earned year interest cost plan participants contributions curtailments settlements plan amendments actuarial losses retiree drug subsidy benefits paid special termination benefits exchange rate lossesgains benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions plan participants contributions settlements retiree drug subsidy benefits paid exchange rate gainslosses fair value plan assets end year funded status assetsliabilities recognized assets accrued expenses pension postretirement liabilities funded status recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service costbenefit total accumulated benefit obligation defined benefit pension plans million million december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matches duration benefit obligations used determining discount rate citigroup pension discount curve used developing discount rate us plans several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years pension postretirement liabilities increased billion december corresponding charge comprehensive income result lower expected return plan assets million actuarial losses attributed benefit obligation million actuarial losses resulted prevailing equity fixed income market conditions reduction interest rates expected return plan assets determined using expected rate return calculated value assets referred marketrelated value marketrelated value exceeded fair value plan assets million december fair value plan assets exceeded marketrelated value million december differences assumed actual returns amortized marketrelated value straightline basis three year period gains losses resulted changes actuarial assumptions changes discount rate differences assumed actual experience differences actual expected return plan assets gains losses except differences amortized market related value amortized extent exceed higher marketrelated value projected benefit obligation respective plan result approximately million related pension benefits expected amortized majority remaining actuarial losses amortized life expectancy plans participants us plans expected remaining service periods plans assumed healthcare cost trend rates december follows healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed healthcare cost trend rates effect amounts reported healthcare plans onepercentagepoint change assumed healthcare cost trend rates would following effects percentage percentage dollars millions point increase point decrease effect total service interest cost effect postretirement benefit obligation plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total equity funds equity securities fixed income funds venture capital limited partnerships government mortgage backed securities corporate debt securities shortterm investment funds us treasury agency securities insurance contracts event driven hedge funds collateralized mortgage obligation bonds state municipal bonds asset backed securities real estate cash cash equivalents total plan assets fair value investment valuation policies per investment class follows level inputs utilize quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange us treasury agency securities cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs include observable prices similar instruments quoted prices identical similar instruments markets active observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds event driven hedge funds shortterm investment funds classified level within fair value hierarchy valued net asset value shares held year end corporate debt securities government mortgage backed securities collateralized mortgage obligation bonds asset backed securities us treasury agency securities state municipal bonds real estate interests classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available equity funds venture capital limited partnership investments classified level within fair value hierarchy valued estimated fair value estimated fair value based fair value underlying investment values cost plus minus accumulated earnings losses approximates fair value insurance contract interests carried contract value approximates estimated fair value based fair value underlying investment insurance company insurance contracts held certain foreign pension plans valuation models corporate debt securities collateralized mortgage obligation bonds asset backed securities classified level within fair value hierarchy based estimated bids brokers thirdparty vendor sources utilize expected cash flow streams collateral values including assessments counterparty credit quality default risk discount rates overall capital market liquidity following summarizes activity financial assets utilizing level fair value measurements venture capital limited insurance dollars millions partnerships contracts total fair value january purchases sales settlements realized lossesgains unrealized gainslosses fair value december purchases sales settlements realized lossesgains unrealized gainslosses fair value december investment strategy emphasizes equities order achieve higher expected returns lower expenses required cash contributions longterm target asset allocation public equity us international private equity fixed income maintained us pension plans investments well diversified within three major asset categories approximately us pension plans equity investments actively managed venture capital limited partnerships typically valued three month lag bristolmyers squibb company common stock represents less plan assets december contributions contributions us pension plans million million million including million mead johnson contributions us pension plans expected approximate million million contributed january contributions international pension plans million million million contributions international plans expected range million million estimated future benefit payments pension dollars millions benefits benefits years savings plan principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match qualified defined contribution plans amended allow increased matching additional company contributions effective expense related plan million million million post employment benefit plan postemployment liabilities longterm disability benefits million december expense related benefits million million termination indemnity plans statutory termination obligations europe recognized undiscounted basis assuming employee termination measurement date liability recognized obligations million december note employee stock benefit plans may shareholders approved stock award incentive plan plan replaced stock incentive plan expired may shares common stock reserved issuance pursuant stock plans options conversions preferred stock million december shares available granted active plans adjusted combination plans million december shares stock option exercise share unit vesting issued treasury stock shares actually delivered participants connection award restrictions lapsed reduce number shares reserved shares tendered prior year pay purchase price options shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably years maximum term years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price common stock may granted key employees subject restrictions continuous employment restrictions expire four year period date grant compensation expense recognized vesting period stock unit right receive stock end specified vesting period voting rights beginning market share units granted certain executives vesting market share units conditioned upon continuous employment vesting date payout factor equals least payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years longterm performance awards three year cycle delivered form target number performance share units number shares ultimately issued calculated based actual performance compared earnings targets performance criteria established beginning performance period awards annual goals maximum payout threshold targets met performance period payment made plan annual period vesting occurs end three year period stockbased compensation expense based awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates stockbased compensation expense follows years ended december dollars millions stock options restricted stock market share units longterm performance awards total stockbased compensation expense continuing operations discontinued operations total stockbased compensation expense deferred tax benefit related stockbased compensation expense sharebased compensation activities follows longterm stock options restricted stock units market share units performance awards weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares thousands outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeited balance december total compensation costs related sharebased payment awards yet recognized weightedaverage period awards expected recognized december follows longterm stock restricted market performance dollars millions options stock units share units awards unrecognized compensation cost expected weightedaverage period years compensation cost recognized additional information related sharebased compensation awards summarized follows amounts millions except per share data weightedaverage grant date fair value per share stock options restricted stock units market share units longterm performance awards fair value options awards vested year stock options restricted stock units market share units longterm performance awards total intrinsic value stock options exercised year following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding options exercisable weighted weighted average weighted average weighted remaining average remaining average number contractual exercise aggregate contractual exercise aggregate outstanding life price per intrinsic number life price per intrinsic range exercise prices thousands years share value exercisable years share value aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december fair value assumptions fair value stock options estimated grant date using blackscholes option pricing model stock options service condition model applying multiple input variables determine probability satisfying market conditions options service market conditions following weightedaverage assumptions used valuation expected volatility riskfree interest rate dividend yield expected life yrs expected volatility assumption required blackscholes model derived calculating year historical volatility weighting equally derived implied volatility blended historical implied volatility approach expected volatility believed representative future stock price trends using historical volatility riskfree interest rate assumption based upon us treasury yield curve effect grant date dividend yield assumption based historical expected dividend payouts expected life stock options represents weightedaverage period stock options remain outstanding derived output latticebinomial model expected life impacted underlying assumptions calibration model model assumes employees exercise behavior function options remaining vested life extent option inthemoney model estimates probability exercise function two variables based historical exercises cancellations prior option grants made fair value restricted stock units longterm performance awards determined based closing trading price companys common stock grant date beginning fair value performance share units granted discounted participate dividends fair value performance share units granted prior discounted using riskfree interest rate date grant participate dividends fair value market share units estimated date grant using model applying multiple input variables determine probability satisfying market conditions model uses following input variables expected volatility riskfree interest rate dividend yield expected volatility based four year historical volatility levels companys common stock current implied volatility fouryear riskfree interest rate derived federal reserve based market share units contractual term expected dividend yield based historical dividend payments note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum rental commitments operating lease expense million million million million included discontinued operations sublease income material years ended december note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial health safety matters consumer fraud employment matters product liability insurance coverage litigation expense net included million insurance reimbursement prior litigation offset additional reserves certain average wholesale prices awp litigation million securities litigation settlement legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product sales generic competition intellectual property plavix litigation us patent infringement litigation apotex related matters previously disclosed companys us territory partnership alliance sanofi plaintiff pending patent infringement lawsuit instituted united states district court southern district new york district court entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex suit based us patent patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel medicine made available us companies plavix also previously reported district court upheld validity enforceability patent maintaining main patent protection plavix us life patent term expires may district court also ruled apotexs generic clopidogrel bisulfate product infringed patent permanently enjoined apotex engaging activity infringes patent including marketing generic product us patent expires apotex appealed district courts decision december united states court appeals federal circuit circuit court affirmed district courts ruling sustaining validity patent apotex filed petition circuit court rehearing en banc march circuit court denied apotexs petition case remanded district court proceedings relating damages july apotex filed petition writ certiorari us supreme court requesting supreme court review circuit courts decision november us supreme court denied petition declining review circuit courts decision december companies filed motion district court summary judgment damages january apotex filed motion seeking stay ongoing damages proceedings pending outcome reexamination plavix patent us patent trademark office pto described april district court denied apotexs motion stay proceedings october district court granted companies summary judgment motion awarded million damages plus costs interest apotex appealed amount damages award however validity patent claiming clopidogrel bisulfate finally judicially determined favor companies maintaining patent protection market exclusivity plavix us may including additional sixmonth pediatric exclusivity period october circuit court upheld million damages award reversed district courts award prejudgment interest february companies received payment million damages award plus costs postjudgment interest bms received million previously disclosed companys us territory partnership alliance sanofi also plaintiff five additional patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuits dr reddys teva cobalt relate patent may dr reddys signed consent judgment favor sanofi bms conceding validity infringement patent previously reported patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex consequently july district court entered judgments cobalt teva permanently enjoined cobalt teva engaging activity infringes patent patent expires cobalt teva filed appeal july circuit court issued mandate teva appeal binding teva decision apotex litigation august cobalt consented entry judgment appeal agreeing bound circuit courts decision apotex litigation lawsuit watson filed october based us patent patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix december court permitted watson pursue declaratory judgment counterclaim respect us patent january court approved parties stipulation stay case pending outcome trial apotex matter may bms watson entered stipulation dismiss case april pharmastar filed request inter partes reexamination patent pto pto granted request july july pto vacated reexamination proceeding lawsuit sun filed july based infringement patent patent respect patent sun agreed bound outcome apotex litigation respect patent parties settled december case dismissed additionally november apotex filed lawsuit new jersey superior court entitled apotex inc et al v sanofiaventis et al seeking payment million plus interest related breakup march proposed settlement agreement april new jersey superior court granted companies crossmotion summary judgment motion denied apotexs motion summary judgment apotex appealed decisions possible time determine outcome appeal new jersey superior courts decisions january apotex filed lawsuit florida state court broward county alleging breach contract relating parties may proposed settlement agreement discovery ongoing plavix litigation international plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex since changed name apotex august apotex filed application federal court australia seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september australian court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full federal court australia held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages expected amount damages material company plavix eu previously disclosed yes pharmaceutical development services gmbh yes pharmaceutical filed application marketing authorization germany alternate salt form clopidogrel application relied data studies originally conducted sanofi bms plavix still subject data protection eu sanofi bms filed action yes pharmaceutical partners administrative court cologne objecting marketing authorization matter currently pending although specific marketing authorizations withdrawn market plavix canada apotex inc april apotex filed impeachment action sanofi federal court canada alleging sanofis canadian patent patent invalid patent covers clopidogrel bisulfate patent issue prohibition action canada previously disclosed canadian federal court ottawa rejected apotexs challenge patent held asserted claims novel obvious infringed granted sanofis application order prohibition minister health apotex precluding approval apotexs abbreviated new drug submission patent expires august decision affirmed appeal federal court appeal supreme court canada june sanofi filed defense impeachment action filed suit apotex infringement patent trial completed june december federal court issued decision patent invalid sanofi appealing decision though generic companies entered market intellectual property litigation abilify previously disclosed otsuka filed patent infringement actions teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun zydus pharmaceuticals usa inc zydus apotex relating us patent patent covers aripiprazole expires april including additional sixmonth pediatric exclusivity period aripiprazole comarketed company otsuka us abilify nonjury trial us district court district new jersey nj district court tevabarr apotex completed august november nj district court upheld validity enforceability patent maintaining main patent protection abilify us april nj district court also ruled defendants generic aripiprazole product infringed patent permanently enjoined engaging activity infringes patent including marketing generic product us patent including sixmonth pediatric extension expires sandoz synthon sun zydus also bound nj district courts decision december tevabarr apotex appealed decision us court appeals federal circuit oral argument held february possible time determine outcome appeal nj district courts decision otsuka prevail appeal generic competition would likely result substantial decreases sales abilify us would material adverse effect results operations cash flows could material financial condition atripla april teva filed anda manufacture market generic version atripla atripla single tablet threedrug regimen combining companys sustiva gileads truvada time companys us patent rights covering sustivas composition matter method use challenged teva sent gilead paragraph iv certification letter challenging two fifteen orange book listed patents atripla atripla product joint venture company gilead may gilead filed patent infringement action teva us district court southern district new york sdny january company received notice teva amended anda challenging eight additional orange book listed patents atripla march company merck sharp dohme corp filed patent infringement action teva also sdny relating two us patents claim crystalline polymorph forms efavirenz march gilead filed two patent infringement actions teva sdny relating six orange book listed patents atripla discovery matters ongoing possible time reasonably assess outcome lawsuits impact company baraclude august teva filed anda manufacture market generic versions baraclude company received paragraph iv certification letter teva challenging one orange book listed patent baraclude us patent september company filed patent infringement lawsuit delaware district court teva infringement listed patent covering baraclude triggered automatic month stay approval tevas anda discovery matter ongoing possible time reasonably assess outcome lawsuit impact company trial currently scheduled october sprycel september apotex filed anda manufacture market generic versions sprycel company received paragraph iv certification letter apotex challenging four orange book listed patents sprycel including composition matter patent november company filed patent infringement lawsuit us district court district new jersey apotex infringement four orange book listed patents covering sprycel triggered automatic month stay approval apotexs anda october company received paragraph iv notice letter apotex informing company seeking approval generic versions mg mg dosage strengths sprycel challenging four orange book listed patents november bms filed patent infringement suit apotex mg mg dosage strengths new jersey district court case consolidated suit filed november discovery matter ongoing possible time reasonably assess outcome lawsuit impact company sustiva eu january teva obtained european marketing authorization efavirenz teva mg tablets february company merck sharp dohme merck filed lawsuits requests injunctions teva netherlands germany uk infringement mercks european patent supplementary protection certificates expiring november possible time reasonably assess outcome lawsuits impact company general commercial litigation clayworth litigation previously disclosed company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants july judgment favor defendants affirmed california court appeals july california supreme court reversed court appeals judgment matter remanded superior court proceedings march defendants motion summary judgment granted judgment entered favor defendants plaintiffs appealed decision pricing sales promotional practices litigation investigations abilify federal subpoena january company received subpoena united states attorneys office southern district new york requesting information related among things sales marketing abilify possible time assess outcome matter potential impact company abilify state attorneys general investigation march company received letter delaware attorney generals office advising multistate coalition investigating whether certain abilify marketing practices violated respective states consumer protection statutes possible time reasonably assess outcome investigation potential impact company awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company defendant four state attorneys general suits pending state courts around country beginning august company defendant trial commonwealth court pennsylvania commonwealth court brought commonwealth pennsylvania september jury issued verdict company finding company liable fraudulent negligent misrepresentation however commonwealth court judge issued decision pennsylvania consumer protection claim go jury finding company liable million enjoining company contributing provision inflated awps company moved vacate decision commonwealth moved judgment notwithstanding verdict court denied company commonwealth appealed decision pennsylvania supreme court qui tam litigation march company served unsealed qui tam complaint filed three former sales representatives california superior court county los angeles california department insurance elected intervene lawsuit complaint alleges company paid kickbacks california providers pharmacies violation california insurance frauds prevention act cal ins code possible time reasonably assess outcome lawsuit impact company product liability litigation company party various product liability lawsuits previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits various federal state courts claiming personal injury damage allegedly sustained using plavix currently claims filed primarily state federal courts new jersey illinois new york pennsylvania company also executed tolling agreement respect unfiled claims potential additional plaintiffs possible time reasonably assess outcome lawsuits potential impact company reglan company one number defendants numerous lawsuits behalf approximately plaintiffs claiming personal injury allegedly sustained using reglan another brand generic drug metoclopramide product indicated gastroesophageal reflux certain gastrointestinal disorders company generic subsidiary apothecon inc distributed metoclopramide tablets manufactured another party possible time reasonably assess outcome lawsuits potential impact company hormone replacement therapy company one number defendants masstort litigation plaintiffs allege among things various hormone therapy products including hormone therapy products formerly manufactured company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clots cardiac injuries women defendants aware risks failed warn consumers company agreed resolve claims approximately plaintiffs december company remains defendant approximately actively pending lawsuits federal state courts throughout us companys hormone therapy products sold companies january august environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated thirdparties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties new brunswick facility environmental personal injury lawsuits since may lawsuits filed company new jersey superior court behalf current former residents new brunswick nj live lived adjacent companys new brunswick facility complaints either allege various personal injuries damages resulting alleged soil groundwater contamination property stemming historical operations new brunswick facility claims medical monitoring portion complaints also assert claims alleged property damage october new jersey supreme court granted mass tort status cases transferred new jersey superior court atlantic county centralized case management purposes company intends defend vigorously litigation discovery ongoing october additional cases filed new jersey superior court removed company federal court trenton nj plaintiffs moved remand cases state court company opposed possible time reasonably assess outcome lawsuits potential impact company north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january new jersey department environmental protection njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means avoid litigation central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted interim funding payments december november parties commenced mediation late however efforts successful parties moved binding allocation process parties expected conduct fact expert discovery followed formal evidentiary hearings written argument hearings likely scheduled midtolate addition september township boe filed suits several parties alleged contributed waste materials site company currently believe responsible additional amounts beyond two interim payments totaling million already transmitted additional possible loss expected material proceedings italy investigation july public prosecutor florence italy italian prosecutor initiated criminal investigation companys subsidiary italy bms italy allegations company relate alleged activities former employee left company italian prosecutor requested interim measure judicial administrator appointed temporarily run operations bms italy request pending florence court possible time assess outcome investigation potential impact company sec germany investigation previously disclosed october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents october sec informed company inquiry become formal secs inquiry encompasses matters formerly investigation german prosecutor munich germany since resolved company understands inquiry concerns potential violations foreign corrupt practices act company cooperating sec note subsequent event february bms completed acquisition outstanding shares inhibitex inc inhibitex clinicalstage biopharmaceutical company focused developing products prevent treat serious infectious diseases aggregate purchase price approximately billion acquisition related costs expected approximate million included expense bms obtained inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase ii development treatment chronic hepatitis c infections well programs various stages development although preliminary purchase price allocation currently process purchase price expected allocated goodwill inx note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earnings less net earnings attributable noncontrolling interest net earnings attributable bms eps basic eps diluted dividends declared per common share cash cash equivalents marketable securities dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earnings less net earnings attributable noncontrolling interest net earnings attributable bms eps basic eps diluted dividends declared per common share cash cash equivalents marketable securities earnings per share quarters may add amounts year period computed discrete basis marketable securities includes current noncurrent assets following specified items affected comparability results dollars millions first quarter second quarter third quarter fourth quarter year provision restructuring accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs gain sale product lines businesses assets litigation chargesrecoveries upfront milestone licensing payments net iprd impairment product liability charges total income taxes items specified tax benefit decrease net earnings relates releases tax reserves specified prior periods dollars millions first quarter second quarter third quarter fourth quarter year provision restructuring impairment loss sale manufacturing operations accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs litigation chargesrecoveries upfront milestone licensing payments iprd impairment acquisition related items product liability charges total income taxes items outofperiod tax adjustment specified tax charge decrease net earnings relates tax charge additional us taxable income earnings foreign subsidiaries previously considered permanently reinvested offshore report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting item b information none report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements company year ended december report dated february expressed unqualified opinion financial statements deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item